787 results on '"Marchesi F."'
Search Results
2. Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population—on behalf of the Italian Research Group for Gastric Cancer
- Author
-
Lombardi, Pietro Maria, Bernasconi, D., Baiocchi, G.L., Berselli, M., Biondi, A., Castoro, C., Catarci, M., Degiuli, M., Fumagalli Romario, U., Giacopuzzi, S., Marchesi, F., Marrelli, D., Mazzola, M., Molfino, S., Olmi, S., Rausei, S., Rosa, F., Rosati, R., Roviello, F., Santi, S., Solaini, L., Staderini, F., Viganò, J., and Ferrari, G.
- Published
- 2022
- Full Text
- View/download PDF
3. Abdominal drainage after elective colorectal surgery: propensity score-matched retrospective analysis of an Italian cohort
- Author
-
Guadagni, S, Catarci, M, Masedu, F, Karim, M, Clementi, M, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Scatizzi, M, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Campagnacci, R, De Luca, R, Ficari, F, Sica, G, Scabini, S, Liverani, A, Caricato, M, Patriti, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Guercioni, G, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Ciano, P, Benedetti, M, Montemurro, L, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Pandolfini, L, Falsetto, A, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Maurizi, A, Simone, M, Giudici, F, Cianchi, F, Sensi, B, Aprile, A, Soriero, D, Scarinci, A, Capolupo, G, Sisti, V, Ricci, M, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Cicconi, S, Marziali, I, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Guadagni S., Catarci M., Masedu F., Karim M. E., Clementi M., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Scatizzi M., Pirozzi F., Delrio P., Garulli G., Marini P., Campagnacci R., De Luca R., Ficari F., Sica G., Scabini S., Liverani A., Caricato M., Patriti A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Guercioni G., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Ciano P., Benedetti M., Montemurro L. A., Mattei M. S., Belloni E., Apa D., Di Carlo M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Pandolfini L., Falsetto A., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Maurizi A., Simone M., Giudici F., Cianchi F., Sensi B., Aprile A., Soriero D., Scarinci A., Capolupo G. T., Sisti V., Ricci M. L., Sagnotta A., Molfino S., Amodio P., Cardinali A., Cicconi S., Marziali I., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., La Gioia G., Guadagni, S, Catarci, M, Masedu, F, Karim, M, Clementi, M, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Scatizzi, M, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Campagnacci, R, De Luca, R, Ficari, F, Sica, G, Scabini, S, Liverani, A, Caricato, M, Patriti, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Guercioni, G, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Ciano, P, Benedetti, M, Montemurro, L, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Pandolfini, L, Falsetto, A, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Maurizi, A, Simone, M, Giudici, F, Cianchi, F, Sensi, B, Aprile, A, Soriero, D, Scarinci, A, Capolupo, G, Sisti, V, Ricci, M, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Cicconi, S, Marziali, I, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Guadagni S., Catarci M., Masedu F., Karim M. E., Clementi M., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Scatizzi M., Pirozzi F., Delrio P., Garulli G., Marini P., Campagnacci R., De Luca R., Ficari F., Sica G., Scabini S., Liverani A., Caricato M., Patriti A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Guercioni G., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Ciano P., Benedetti M., Montemurro L. A., Mattei M. S., Belloni E., Apa D., Di Carlo M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Pandolfini L., Falsetto A., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Maurizi A., Simone M., Giudici F., Cianchi F., Sensi B., Aprile A., Soriero D., Scarinci A., Capolupo G. T., Sisti V., Ricci M. L., Sagnotta A., Molfino S., Amodio P., Cardinali A., Cicconi S., Marziali I., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., and La Gioia G.
- Abstract
Background: In Italy, surgeons continue to drain the abdominal cavity in more than 50 per cent of patients after colorectal resection. The aim of this study was to evaluate the impact of abdominal drain placement on early adverse events in patients undergoing elective colorectal surgery. Methods: A database was retrospectively analysed through a 1:1 propensity score-matching model including 21 covariates. The primary endpoint was the postoperative duration of stay, and the secondary endpoints were surgical site infections, infectious morbidity rate defined as surgical site infections plus pulmonary infections plus urinary infections, anastomotic leakage, overall morbidity rate, major morbidity rate, reoperation and mortality rates. The results of multiple logistic regression analyses were presented as odds ratios (OR) and 95 per cent c.i. Results: A total of 6157 patients were analysed to produce two well-balanced groups of 1802 patients: group (A), no abdominal drain(s) and group (B), abdominal drain(s). Group A versus group B showed a significantly lower risk of postoperative duration of stay >6 days (OR 0.60; 95 per cent c.i. 0.51–0.70; P < 0.001). A mean postoperative duration of stay difference of 0.86 days was detected between groups. No difference was recorded between the two groups for all the other endpoints. Conclusion: This study confirms that placement of abdominal drain(s) after elective colorectal surgery is associated with a non-clinically significant longer (0.86 days) postoperative duration of stay but has no impact on any other secondary outcomes, confirming that abdominal drains should not be used routinely in colorectal surgery.
- Published
- 2024
4. Mechanical bowel preparation in elective colorectal surgery: a propensity score-matched analysis of the Italian colorectal anastomotic leakage (iCral) study group prospective cohorts
- Author
-
Catarci, M, Guadagni, S, Masedu, F, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Patriti, A, Campagnacci, R, Sica, G, Caricato, M, Montemurro, L, Ciano, P, Benedetti, M, Guercioni, G, Scatizzi, M, De Luca, R, Ficari, F, Scabini, S, Liverani, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Cicconi, S, Marziali, I, Clementi, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Sisti, V, Ricci, M, Maurizi, A, Sensi, B, Capolupo, G, Pandolfini, L, Falsetto, A, Simone, M, Giudici, F, Cianchi, F, Baldini, G, Aprile, A, Soriero, D, Scarinci, A, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Lisi, G, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Catarci M., Guadagni S., Masedu F., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Pirozzi F., Delrio P., Garulli G., Marini P., Patriti A., Campagnacci R., Sica G., Caricato M., Montemurro L. A., Ciano P., Benedetti M., Guercioni G., Scatizzi M., De Luca R., Ficari F., Scabini S., Liverani A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Mattei M. S., Belloni E., Apa D., Di Carlo M., Cicconi S., Marziali I., Clementi M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Sisti V., Ricci M. L., Maurizi A., Sensi B., Capolupo G. T., Pandolfini L., Falsetto A., Simone M., Giudici F., Cianchi F., Baldini G., Aprile A., Soriero D., Scarinci A., Sagnotta A., Molfino S., Amodio P., Cardinali A., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Lisi G., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., La Gioia G., Catarci, M, Guadagni, S, Masedu, F, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Patriti, A, Campagnacci, R, Sica, G, Caricato, M, Montemurro, L, Ciano, P, Benedetti, M, Guercioni, G, Scatizzi, M, De Luca, R, Ficari, F, Scabini, S, Liverani, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Cicconi, S, Marziali, I, Clementi, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Sisti, V, Ricci, M, Maurizi, A, Sensi, B, Capolupo, G, Pandolfini, L, Falsetto, A, Simone, M, Giudici, F, Cianchi, F, Baldini, G, Aprile, A, Soriero, D, Scarinci, A, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Lisi, G, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Catarci M., Guadagni S., Masedu F., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Pirozzi F., Delrio P., Garulli G., Marini P., Patriti A., Campagnacci R., Sica G., Caricato M., Montemurro L. A., Ciano P., Benedetti M., Guercioni G., Scatizzi M., De Luca R., Ficari F., Scabini S., Liverani A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Mattei M. S., Belloni E., Apa D., Di Carlo M., Cicconi S., Marziali I., Clementi M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Sisti V., Ricci M. L., Maurizi A., Sensi B., Capolupo G. T., Pandolfini L., Falsetto A., Simone M., Giudici F., Cianchi F., Baldini G., Aprile A., Soriero D., Scarinci A., Sagnotta A., Molfino S., Amodio P., Cardinali A., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Lisi G., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., and La Gioia G.
- Abstract
Retrospective evaluation of the effects of mechanical bowel preparation (MBP) on data derived from two prospective open-label observational multicenter studies in Italy regarding elective colorectal surgery. MBP for elective colorectal surgery remains a controversial issue with contrasting recommendations in current guidelines. The Italian ColoRectal Anastomotic Leakage (iCral) study group, therefore, decided to estimate the effects of no MBP (treatment variable) versus MBP for elective colorectal surgery. A total of 8359 patients who underwent colorectal resection with anastomosis were enrolled in two consecutive prospective studies in 78 surgical centers in Italy from January 2019 to September 2021. A retrospective PSMA was performed on 5455 (65.3%) cases after the application of explicit exclusion criteria to eliminate confounders. The primary endpoints were anastomotic leakage (AL) and surgical site infections (SSI) rates; the secondary endpoints included SSI subgroups, overall and major morbidity, reoperation, and mortality rates. Overall length of postoperative hospital stay (LOS) was also considered. Two well-balanced groups of 1125 patients each were generated: group A (No MBP, true population of interest), and group B (MBP, control population), performing a PSMA considering 21 covariates. Group A vs. group B resulted significantly associated with a lower risk of AL [42 (3.5%) vs. 73 (6.0%) events; OR 0.57; 95% CI 0.38–0.84; p = 0.005]. No difference was recorded between the two groups for SSI [73 (6.0%) vs. 85 (7.0%) events; OR 0.88; 95% CI 0.63–1.22; p = 0.441]. Regarding the secondary endpoints, no MBP resulted significantly associated with a lower risk of reoperation and LOS > 6 days. This study confirms that no MBP before elective colorectal surgery is significantly associated with a lower risk of AL, reoperation rate, and LOS < 6 days when compared with MBP.
- Published
- 2024
5. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
- Author
-
Salmanton-Garcia, J., Marchesi, F., Farina, F., Weinbergerova, B., Itri, F., Davila-Valls, J., Martin-Perez, S., Glenthoj, A., Hersby, D. S., Gomes da Silva, M., Nunes Rodrigues, R., Lopez-Garcia, A., Cordoba, R., Bilgin, Y. M., Falces-Romero, I., El-Ashwah, S., Emarah, Z., Besson, C., Kohn, M., Van Doesum, J., Ammatuna, E., Marchetti, M., Labrador, J., Zambrotta, G. P. M., Verga, L., Jaksic, O., Nucci, M., Piukovics, K., Cabirta-Touzon, A., Jimenez, M., Arellano, E., Espigado, I., Blennow, O., Nordlander, A., Meers, S., van Praet, J., Aiello, T. F., Garcia-Vidal, C., Fracchiolla, N., Sciume, M., Seval, G. C., Zak, P., Buquicchio, C., Tascini, C., Grafe, S. K., Schonlein, M., Adzic-Vukicevic, T., Bonuomo, V., Cattaneo, C., Nizamuddin, S., Cernan, M., Plantefeve, G., Prin, R., Szotkovski, T., Collins, G. P., Dargenio, M., Petzer, V., Wolf, D., Colovic, N., Prezioso, L., Valkovic, T., Passamonti, F., Mendez, G. -A., Sili, U., Vena, A., Bavastro, M., Limongelli, A., Duarte, R. F., Ledoux, M. -P., Cvetanoski, M., Stojanoski, Z., Machado, M., Batinic, J., Magliano, G., Biernat, M. M., Pantic, N., Poulsen, C. B., Cuccaro, A., Del Principe, M. I., Kulasekararaj, A., Ormazabal-Velez, I., Busca, A., Demirkan, F., Ijaz, M., Klimko, N., Stoma, I., Khostelidi, S., Fernandez, N., Omrani, A. S., Bergantim, R., De Jonge, N., Fouquet, G., Navratil, M., Abu-Zeinah, G., Samarkos, M., Maertens, J., De Ramon, C., Guidetti, A., Magyari, F., Gonzalez-Lopez, T. J., Lahmer, T., Finizio, O., Ali, N., Pinczes, L. I., Lavilla-Rubira, E., Romano, A., Merelli, M., Delia, M., Calbacho, M., Meletiadis, J., Antic, D., Hernandez-Rivas, J. -A., Marques de Almeida, J., Al-Khabori, M., Hoenigl, M., Tisi, M. C., Khanna, N., Barac, A., Eisa, N., Di Blasi, R., Lievin, R., Miranda-Castillo, C., Bahr, N. C., Lamure, S., Papa, M. V., Yahya, A., Aujayeb, A., Novak, J., Erben, N., Fernandez-Galan, M., Ribera-Santa Susana, J. -M., Rinaldi, I., Fazzi, R., Piedimonte, M., Dulery, R., Gonzaga, Y., Soto-Silva, A., Sapienza, G., Serris, A., Drgona, Groh, A., Serrano, L., Gavriilaki, E., Tragiannidis, A., Prattes, J., Coppola, N., Otasevic, V., Mladenovic, M., Mitrovic, M., Miskovic, B., Jindra, P., Zompi, S., Sacchi, M. V., Krekeler, C., Infante, M. S., Garcia-Bordallo, D., Colak, G. M., Mayer, J., Nygaard, M., Hanakova, M., Racil, Z., Bonanni, Matteo, Koehler, P., Rahimli, L., Cornely, O. A., Pagano, Livio, Martin-Vallejo, F. J., Zdziarski, P., Zarrinfer, H., Wittig, J., Win, S., Wai-Man, V., Visek, B., Vinh, D. C., Vehreschild, M., Varricchio, G., Tsirigotis, P., Torres-Tienza, A., Tanase, A. D., Tafuri, A., Stamouli, M., Sramek, J., Soussain, C., Shirinova, A., Schubert, J., Schalk, E., Salehi, M. R., Saleh, M., Rosati, G., Roldan, E., Reizine, F., Rego, M., Regalado-Artamendi, I., Popova, M., Pinto, F., Philippe, L., Orth, H. M., Ommen, H. -B., Obr, A., Nunez-Martin-Buitrago, L., Noel, N., Neuhann, J., Nadali, G., Nacov, J. A., Munhoz Alburquerque, A. M., Mitra, M. E., Mikulska, M., Mellinghoff, S., Mechtel, B., Martin-Gonzalez, J. -A., Malak, S., Loureiro-Amigo, J., Lorenzo De La Pena, L., Liberti, G., Landau, M., Lacej, I., Kolditz, M., Kho, C. S., Khedr, R. A., Karthaus, M., Karlsson, L. K., Jimenez-Lorenzo, M. -J., Izuzquiza, M., Hoell-Neugebauer, B., Herbrecht, R., Heath, C. H., Guolo, F., Grothe, J., Giordano, A., Gerasymchuk, S., Garcia-Sanz, R., Garcia-Pouton, N., Funke, V. A. M., Fung, M., Flasshove, C., Fianchi, Luana, Essame, J., Egger, M., Drenou, B., Dragonetti, G., Desole, M., Della Pepa, R., Deau Fischer, B., De Kort, E., De Cabo, E., Danion, F., Daguindau, E., Cushion, T., Cremer, L., Criscuolo, Marianna, Cordini, G., Cingolani, Antonella, Ciceri, F., Chowdhury, F. R., Chelysheva, E., Chauchet, A., Chai, L. Y. A., Ceesay, M. M., Busch, E., Brehon, M., Borducchi, D. M. M., Booth, S., Bologna, S., Berg Venemyr, C., Bailen-Almorox, R., Antoniadou, A., Anastasopoulou, A. N., Altuntas, F., Bonanni M., Pagano L. (ORCID:0000-0001-8287-928X), Fianchi L., Criscuolo M., Cingolani A. (ORCID:0000-0002-3793-2755), Salmanton-Garcia, J., Marchesi, F., Farina, F., Weinbergerova, B., Itri, F., Davila-Valls, J., Martin-Perez, S., Glenthoj, A., Hersby, D. S., Gomes da Silva, M., Nunes Rodrigues, R., Lopez-Garcia, A., Cordoba, R., Bilgin, Y. M., Falces-Romero, I., El-Ashwah, S., Emarah, Z., Besson, C., Kohn, M., Van Doesum, J., Ammatuna, E., Marchetti, M., Labrador, J., Zambrotta, G. P. M., Verga, L., Jaksic, O., Nucci, M., Piukovics, K., Cabirta-Touzon, A., Jimenez, M., Arellano, E., Espigado, I., Blennow, O., Nordlander, A., Meers, S., van Praet, J., Aiello, T. F., Garcia-Vidal, C., Fracchiolla, N., Sciume, M., Seval, G. C., Zak, P., Buquicchio, C., Tascini, C., Grafe, S. K., Schonlein, M., Adzic-Vukicevic, T., Bonuomo, V., Cattaneo, C., Nizamuddin, S., Cernan, M., Plantefeve, G., Prin, R., Szotkovski, T., Collins, G. P., Dargenio, M., Petzer, V., Wolf, D., Colovic, N., Prezioso, L., Valkovic, T., Passamonti, F., Mendez, G. -A., Sili, U., Vena, A., Bavastro, M., Limongelli, A., Duarte, R. F., Ledoux, M. -P., Cvetanoski, M., Stojanoski, Z., Machado, M., Batinic, J., Magliano, G., Biernat, M. M., Pantic, N., Poulsen, C. B., Cuccaro, A., Del Principe, M. I., Kulasekararaj, A., Ormazabal-Velez, I., Busca, A., Demirkan, F., Ijaz, M., Klimko, N., Stoma, I., Khostelidi, S., Fernandez, N., Omrani, A. S., Bergantim, R., De Jonge, N., Fouquet, G., Navratil, M., Abu-Zeinah, G., Samarkos, M., Maertens, J., De Ramon, C., Guidetti, A., Magyari, F., Gonzalez-Lopez, T. J., Lahmer, T., Finizio, O., Ali, N., Pinczes, L. I., Lavilla-Rubira, E., Romano, A., Merelli, M., Delia, M., Calbacho, M., Meletiadis, J., Antic, D., Hernandez-Rivas, J. -A., Marques de Almeida, J., Al-Khabori, M., Hoenigl, M., Tisi, M. C., Khanna, N., Barac, A., Eisa, N., Di Blasi, R., Lievin, R., Miranda-Castillo, C., Bahr, N. C., Lamure, S., Papa, M. V., Yahya, A., Aujayeb, A., Novak, J., Erben, N., Fernandez-Galan, M., Ribera-Santa Susana, J. -M., Rinaldi, I., Fazzi, R., Piedimonte, M., Dulery, R., Gonzaga, Y., Soto-Silva, A., Sapienza, G., Serris, A., Drgona, Groh, A., Serrano, L., Gavriilaki, E., Tragiannidis, A., Prattes, J., Coppola, N., Otasevic, V., Mladenovic, M., Mitrovic, M., Miskovic, B., Jindra, P., Zompi, S., Sacchi, M. V., Krekeler, C., Infante, M. S., Garcia-Bordallo, D., Colak, G. M., Mayer, J., Nygaard, M., Hanakova, M., Racil, Z., Bonanni, Matteo, Koehler, P., Rahimli, L., Cornely, O. A., Pagano, Livio, Martin-Vallejo, F. J., Zdziarski, P., Zarrinfer, H., Wittig, J., Win, S., Wai-Man, V., Visek, B., Vinh, D. C., Vehreschild, M., Varricchio, G., Tsirigotis, P., Torres-Tienza, A., Tanase, A. D., Tafuri, A., Stamouli, M., Sramek, J., Soussain, C., Shirinova, A., Schubert, J., Schalk, E., Salehi, M. R., Saleh, M., Rosati, G., Roldan, E., Reizine, F., Rego, M., Regalado-Artamendi, I., Popova, M., Pinto, F., Philippe, L., Orth, H. M., Ommen, H. -B., Obr, A., Nunez-Martin-Buitrago, L., Noel, N., Neuhann, J., Nadali, G., Nacov, J. A., Munhoz Alburquerque, A. M., Mitra, M. E., Mikulska, M., Mellinghoff, S., Mechtel, B., Martin-Gonzalez, J. -A., Malak, S., Loureiro-Amigo, J., Lorenzo De La Pena, L., Liberti, G., Landau, M., Lacej, I., Kolditz, M., Kho, C. S., Khedr, R. A., Karthaus, M., Karlsson, L. K., Jimenez-Lorenzo, M. -J., Izuzquiza, M., Hoell-Neugebauer, B., Herbrecht, R., Heath, C. H., Guolo, F., Grothe, J., Giordano, A., Gerasymchuk, S., Garcia-Sanz, R., Garcia-Pouton, N., Funke, V. A. M., Fung, M., Flasshove, C., Fianchi, Luana, Essame, J., Egger, M., Drenou, B., Dragonetti, G., Desole, M., Della Pepa, R., Deau Fischer, B., De Kort, E., De Cabo, E., Danion, F., Daguindau, E., Cushion, T., Cremer, L., Criscuolo, Marianna, Cordini, G., Cingolani, Antonella, Ciceri, F., Chowdhury, F. R., Chelysheva, E., Chauchet, A., Chai, L. Y. A., Ceesay, M. M., Busch, E., Brehon, M., Borducchi, D. M. M., Booth, S., Bologna, S., Berg Venemyr, C., Bailen-Almorox, R., Antoniadou, A., Anastasopoulou, A. N., Altuntas, F., Bonanni M., Pagano L. (ORCID:0000-0001-8287-928X), Fianchi L., Criscuolo M., and Cingolani A. (ORCID:0000-0002-3793-2755)
- Abstract
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe
- Published
- 2024
6. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
- Author
-
Musto, P., Salmanton-Garcia, J., Sgherza, N., Bergantim, R., Farina, F., Glenthoj, A., Cengiz Seval, G., Weinbergerova, B., Bonuomo, V., Bilgin, Y. M., van Doesum, J., Jaksic, O., Visek, B., Falces-Romero, I., Marchetti, M., Davila-Valls, J., Martin-Perez, S., Nucci, M., Lopez-Garcia, A., Itri, F., Buquicchio, C., Verga, L., Piukovics, K., Navratil, M., Collins, G. P., Jimenez, M., Fracchiolla, N. S., Labrador, J., Prezioso, L., Rossi, E., Colovic, N., Meers, S., Kulasekararaj, A., Cuccaro, A., Blennow, O., Valkovic, T., Sili, U., Ledoux, M. -P., Batinic, J., Passamonti, F., Machado, M., Duarte, R. F., Poulsen, C. B., Mendez, G. -A., Espigado, I., Demirkan, F., Cernan, M., Cattaneo, C., Petzer, V., Magliano, G., Garcia-Vidal, C., El-Ashwah, S., Gomes-Da-Silva, M., Vena, A., Ormazabal-Velez, I., van Praet, J., Dargenio, M., De-Ramon, C., Del Principe, M. I., Marques-De-Almeida, J., Wolf, D., Szotkowski, T., Obr, A., Colak, G. M., Nordlander, A., Izuzquiza, M., Cabirta, A., Zambrotta, G. P. M., Cordoba, R., Zak, P., Ammatuna, E., Mayer, J., Ilhan, O., Garcia-Sanz, R., Quattrone, Martina, Arellano, E., Nunes-Rodrigues, R., Emarah, Z., Aiello, T. F., Hanakova, M., Racil, Z., Bavastro, M., Limongelli, A., Rahimli, L., Marchesi, F., Cornely, O. A., Pagano, Livio, Quattrone M., Pagano L. (ORCID:0000-0001-8287-928X), Musto, P., Salmanton-Garcia, J., Sgherza, N., Bergantim, R., Farina, F., Glenthoj, A., Cengiz Seval, G., Weinbergerova, B., Bonuomo, V., Bilgin, Y. M., van Doesum, J., Jaksic, O., Visek, B., Falces-Romero, I., Marchetti, M., Davila-Valls, J., Martin-Perez, S., Nucci, M., Lopez-Garcia, A., Itri, F., Buquicchio, C., Verga, L., Piukovics, K., Navratil, M., Collins, G. P., Jimenez, M., Fracchiolla, N. S., Labrador, J., Prezioso, L., Rossi, E., Colovic, N., Meers, S., Kulasekararaj, A., Cuccaro, A., Blennow, O., Valkovic, T., Sili, U., Ledoux, M. -P., Batinic, J., Passamonti, F., Machado, M., Duarte, R. F., Poulsen, C. B., Mendez, G. -A., Espigado, I., Demirkan, F., Cernan, M., Cattaneo, C., Petzer, V., Magliano, G., Garcia-Vidal, C., El-Ashwah, S., Gomes-Da-Silva, M., Vena, A., Ormazabal-Velez, I., van Praet, J., Dargenio, M., De-Ramon, C., Del Principe, M. I., Marques-De-Almeida, J., Wolf, D., Szotkowski, T., Obr, A., Colak, G. M., Nordlander, A., Izuzquiza, M., Cabirta, A., Zambrotta, G. P. M., Cordoba, R., Zak, P., Ammatuna, E., Mayer, J., Ilhan, O., Garcia-Sanz, R., Quattrone, Martina, Arellano, E., Nunes-Rodrigues, R., Emarah, Z., Aiello, T. F., Hanakova, M., Racil, Z., Bavastro, M., Limongelli, A., Rahimli, L., Marchesi, F., Cornely, O. A., Pagano, Livio, Quattrone M., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
- Published
- 2024
7. Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape
- Author
-
Vena, A., Bassetti, M., Mezzogori, L., Marchesi, F., Hoenigl, M., Giacobbe, D. R., Corcione, S., Bartoletti, M., Stemler, J., Pagano, Livio, Cornely, O. A., Salmanton-Garcia, J., Pagano L. (ORCID:0000-0001-8287-928X), Vena, A., Bassetti, M., Mezzogori, L., Marchesi, F., Hoenigl, M., Giacobbe, D. R., Corcione, S., Bartoletti, M., Stemler, J., Pagano, Livio, Cornely, O. A., Salmanton-Garcia, J., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Background: We assessed the laboratory diagnosis and treatment of invasive fungal disease (IFD) in Italy to detect limitations and potential for improvement. Methods: The survey was available online at www.clinicalsurveys.net/uc/IFI management capacity/, and collected variables such as (a) institution profile, (b) perceptions of IFD in the respective institution, (c) microscopy, (d) culture and fungal identification, (e) serology, (f) antigen detection, (g) molecular tests, (h) susceptibility testing and (i) therapeutic drug monitoring (TDM). Results: The laboratory capacity study received responses from 49 Italian centres, with an equitable geographical distribution of locations. The majority of respondents (n = 36, 73%) assessed the occurrence of IFD as moderate-high, with Aspergillus spp. being the pathogen of highest concern, followed by Candida spp. and Mucorales. Although 46 (94%) of the institutions had access to microscopy, less than half of them performed direct microscopy on clinical specimens always when IFD was suspected. Cultures were available in all assessed laboratories, while molecular testing and serology were available in 41 (83%), each. Antigen detection tests and antifungal drugs were also generally accessible (> 90%) among the participating institutions. Nevertheless, access to TDM was limited (n = 31, 63%), with a significant association established between therapeutic drug monitoring availability and higher gross domestic product per capita. Conclusions: Apart from TDM, Italy is adequately prepared for the diagnosis and treatment of IFD, with no significant disparities depending on gross domestic product. Future efforts may need to focus on enhancing the availability and application of direct microscopic methods, as well as TDM, to promote optimal treatment and better patient outcomes.
- Published
- 2024
8. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
- Author
-
El-Ashwah, S., Salmanton-Garcia, J., Bilgin, Y. M., Itri, F., Zak, P., Weinbergerova, B., Verga, L., Omrani, A. S., Silva, M. G. D., Szotkowski, T., Marchetti, M., Buquicchio, C., Nucci, M., Schonlein, M., Farina, F., Besson, C., Prezioso, L., Nizamuddin, S., Davila-Valls, J., Martin-Perez, S., Bonuomo, V., Van Doesum, J., Tisi, M. C., Passamonti, F., Mendez, G. -A., Meers, S., Maertens, J., Lopez-Garcia, A., Glenthoj, A., Bonnani, M., Rinaldi, I., Ormazabal-Velez, I., Labrador, J., Kulasekararaj, A., Espigado, I., Demirkan, F., De Jonge, N., Collins, G. P., Calbacho, M., Blennow, O., Al-Khabori, M., Adzic-Vukicevic, T., Arellano, E., Miskovic, B., Mladenovic, M., Nordlander, A., Racil, Z., Ammatuna, E., Cordoba, R., Hersby, D. S., Grafe, S., Emarah, Z., Hanakova, M., Sacchi, M. V., Ijaz, M., Rahimli, L., Nunes Rodrigues, R., Zambrotta, G. P. M., Marchesi, F., Cornely, O. A., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), El-Ashwah, S., Salmanton-Garcia, J., Bilgin, Y. M., Itri, F., Zak, P., Weinbergerova, B., Verga, L., Omrani, A. S., Silva, M. G. D., Szotkowski, T., Marchetti, M., Buquicchio, C., Nucci, M., Schonlein, M., Farina, F., Besson, C., Prezioso, L., Nizamuddin, S., Davila-Valls, J., Martin-Perez, S., Bonuomo, V., Van Doesum, J., Tisi, M. C., Passamonti, F., Mendez, G. -A., Meers, S., Maertens, J., Lopez-Garcia, A., Glenthoj, A., Bonnani, M., Rinaldi, I., Ormazabal-Velez, I., Labrador, J., Kulasekararaj, A., Espigado, I., Demirkan, F., De Jonge, N., Collins, G. P., Calbacho, M., Blennow, O., Al-Khabori, M., Adzic-Vukicevic, T., Arellano, E., Miskovic, B., Mladenovic, M., Nordlander, A., Racil, Z., Ammatuna, E., Cordoba, R., Hersby, D. S., Grafe, S., Emarah, Z., Hanakova, M., Sacchi, M. V., Ijaz, M., Rahimli, L., Nunes Rodrigues, R., Zambrotta, G. P. M., Marchesi, F., Cornely, O. A., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
- Published
- 2024
9. Three-row versus two-row circular staplers for left-sided colorectal anastomosis: a propensity score-matched analysis of the iCral 2 and 3 prospective cohorts
- Author
-
Catarci, M, Guadagni, S, Masedu, F, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Scatizzi, M, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Campagnacci, R, De Luca, R, Ficari, F, Sica, G, Scabini, S, Liverani, A, Caricato, M, Patriti, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Guercioni, G, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Ciano, P, Benedetti, M, Montemurro, L, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Clementi, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Pandolfini, L, Falsetto, A, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Maurizi, A, Simone, M, Giudici, F, Cianchi, F, Baldini, G, Sensi, B, Aprile, A, Soriero, D, Scarinci, A, Capolupo, G, Sisti, V, Ricci, M, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Cicconi, S, Marziali, I, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Lisi, G, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Catarci M., Guadagni S., Masedu F., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Scatizzi M., Pirozzi F., Delrio P., Garulli G., Marini P., Campagnacci R., De Luca R., Ficari F., Sica G., Scabini S., Liverani A., Caricato M., Patriti A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Guercioni G., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Ciano P., Benedetti M., Montemurro L. A., Mattei M. S., Belloni E., Apa D., Di Carlo M., Clementi M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Pandolfini L., Falsetto A., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Maurizi A., Simone M., Giudici F., Cianchi F., Baldini G., Sensi B., Aprile A., Soriero D., Scarinci A., Capolupo G. T., Sisti V., Ricci M. L., Sagnotta A., Molfino S., Amodio P., Cardinali A., Cicconi S., Marziali I., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Lisi G., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., La Gioia G., Catarci, M, Guadagni, S, Masedu, F, Ruffo, G, Viola, M, Borghi, F, Baldazzi, G, Scatizzi, M, Pirozzi, F, Delrio, P, Garulli, G, Marini, P, Campagnacci, R, De Luca, R, Ficari, F, Sica, G, Scabini, S, Liverani, A, Caricato, M, Patriti, A, Mancini, S, Baiocchi, G, Santoro, R, Siquini, W, Guercioni, G, Basti, M, Pedrazzani, C, Totis, M, Carrara, A, Lucchi, A, Pavanello, M, Muratore, A, D'Ugo, S, Di Leo, A, Pignata, G, Elmore, U, Anania, G, Carlini, M, Corcione, F, Vettoretto, N, Longo, G, Sorrentino, M, Giuliani, A, Ferrari, G, Taglietti, L, Verzelli, A, Di Cosmo, M, Cavaliere, D, Milone, M, Rausei, S, Ciaccio, G, Tebala, G, Brisinda, G, Berti, S, Millo, P, Boni, L, Guerrieri, M, Persiani, R, Parini, D, Spinelli, A, Genna, M, Bottino, V, Coratti, A, Scala, D, Rivolta, U, Piccoli, M, Talarico, C, Roviello, F, Anastasi, A, Ettorre, G, Montuori, M, Mariani, P, de Manzini, N, Donini, A, Armellino, M, Feo, C, Guerriero, S, Costanzi, A, Marchesi, F, Cicetti, M, Ciano, P, Benedetti, M, Montemurro, L, Mattei, M, Belloni, E, Apa, D, Di Carlo, M, Clementi, M, Bertocchi, E, Masini, G, Altamura, A, Rubichi, F, Cianflocca, D, Migliore, M, Cassini, D, Pandolfini, L, Falsetto, A, Sciuto, A, Pace, U, Bucci, A, Monari, F, Attina, G, Maurizi, A, Simone, M, Giudici, F, Cianchi, F, Baldini, G, Sensi, B, Aprile, A, Soriero, D, Scarinci, A, Capolupo, G, Sisti, V, Ricci, M, Sagnotta, A, Molfino, S, Amodio, P, Cardinali, A, Cicconi, S, Marziali, I, Frazzini, D, Conti, C, Tamini, N, Braga, M, Motter, M, Tirone, G, Martorelli, G, Cacurri, A, Di Marco, C, Marsanic, P, Federico, N, Spampinato, M, Crepaz, L, Andreuccetti, J, Canfora, I, Maggi, G, Chiozza, M, Spoletini, D, Marcellinaro, R, Lisi, G, Bracale, U, Peltrini, R, Di Nuzzo, M, Botteri, E, Santoni, S, Stefanoni, M, Del Vecchio, G, Magistro, C, Ruggiero, S, Birindelli, A, Budassi, A, Zigiotto, D, Solaini, L, Ercolani, G, De Palma, G, Tenconi, S, Locurto, P, Di Cintio, A, Chiarello, M, Cariati, M, Gennai, A, Grivon, M, Cassinotti, E, Ortenzi, M, Biondi, A, De Luca, M, Carrano, F, Fior, F, Ferronetti, A, Giuliani, G, Marino, G, Bertoglio, C, Pecchini, F, Greco, V, Piagnerelli, R, Canonico, G, Colasanti, M, Pinotti, E, Carminati, R, Osenda, E, Graziosi, L, De Martino, C, Ioia, G, Pindozzi, F, Organetti, L, Monteleone, M, Dalmonte, G, La Gioia, G, Catarci M., Guadagni S., Masedu F., Ruffo G., Viola M. G., Borghi F., Baldazzi G., Scatizzi M., Pirozzi F., Delrio P., Garulli G., Marini P., Campagnacci R., De Luca R., Ficari F., Sica G., Scabini S., Liverani A., Caricato M., Patriti A., Mancini S., Baiocchi G. L., Santoro R., Siquini W., Guercioni G., Basti M., Pedrazzani C., Totis M., Carrara A., Lucchi A., Pavanello M., Muratore A., D'Ugo S., Di Leo A., Pignata G., Elmore U., Anania G., Carlini M., Corcione F., Vettoretto N., Longo G., Sorrentino M., Giuliani A., Ferrari G., Taglietti L., Verzelli A., Di Cosmo M., Cavaliere D., Milone M., Rausei S., Ciaccio G., Tebala G., Brisinda G., Berti S., Millo P., Boni L., Guerrieri M., Persiani R., Parini D., Spinelli A., Genna M., Bottino V., Coratti A., Scala D., Rivolta U., Piccoli M., Talarico C., Roviello F., Anastasi A., Ettorre G. M., Montuori M., Mariani P., de Manzini N., Donini A., Armellino M. F., Feo C., Guerriero S., Costanzi A., Marchesi F., Cicetti M., Ciano P., Benedetti M., Montemurro L. A., Mattei M. S., Belloni E., Apa D., Di Carlo M., Clementi M., Bertocchi E., Masini G., Altamura A., Rubichi F., Cianflocca D., Migliore M., Cassini D., Pandolfini L., Falsetto A., Sciuto A., Pace U., Bucci A. F., Monari F., Attina G. M., Maurizi A., Simone M., Giudici F., Cianchi F., Baldini G., Sensi B., Aprile A., Soriero D., Scarinci A., Capolupo G. T., Sisti V., Ricci M. L., Sagnotta A., Molfino S., Amodio P., Cardinali A., Cicconi S., Marziali I., Frazzini D., Conti C., Tamini N., Braga M., Motter M., Tirone G., Martorelli G., Cacurri A., Di Marco C., Marsanic P., Federico N. S. P., Spampinato M., Crepaz L., Andreuccetti J., Canfora I., Maggi G., Chiozza M., Spoletini D., Marcellinaro R., Lisi G., Bracale U., Peltrini R., Di Nuzzo M. M., Botteri E., Santoni S., Stefanoni M., Del Vecchio G., Magistro C., Ruggiero S., Birindelli A., Budassi A., Zigiotto D., Solaini L., Ercolani G., De Palma G. D., Tenconi S., Locurto P., Di Cintio A., Chiarello M. M., Cariati M., Gennai A., Grivon M., Cassinotti E., Ortenzi M., Biondi A., De Luca M., Carrano F., Fior F., Ferronetti A., Giuliani G., Marino G., Bertoglio C. L., Pecchini F., Greco V., Piagnerelli R., Canonico G., Colasanti M., Pinotti E., Carminati R., Osenda E., Graziosi L., De Martino C., Ioia G., Pindozzi F., Organetti L., Monteleone M., Dalmonte G., and La Gioia G.
- Abstract
Background: Since most anastomoses after left-sided colorectal resections are performed with a circular stapler, any technological change in stapling devices may influence the incidence of anastomotic adverse events. The aim of the present study was to analyze the effect of a three-row circular stapler on anastomotic leakage and related morbidity after left-sided colorectal resections. Materials and methods: A circular stapled anastomosis was performed in 4255 (50.9%) out of 8359 patients enrolled in two prospective multicenter studies in Italy, and, after exclusion criteria to reduce heterogeneity, 2799 (65.8%) cases were retrospectively analyzed through a 1:1 propensity score-matching model including 20 covariates relative to patient characteristics, to surgery and to perioperative management. Two well-balanced groups of 425 patients each were obtained: group (A) – true population of interest, anastomosis performed with a three-row circular stapler; group (B) – control population, anastomosis performed with a two-row circular stapler. The target of inferences was the average treatment effect in the treated (ATT). The primary endpoints were overall and major anastomotic leakage and overall anastomotic bleeding; the secondary endpoints were overall and major morbidity and mortality rates. The results of multiple logistic regression analyses for the outcomes, including the 20 covariates selected for matching, were presented as odds ratios (OR) and 95% confidence intervals (95% CI). Results: Group A versus group B showed a significantly lower risk of overall anastomotic leakage (2.1 vs. 6.1%; OR 0.33; 95% CI 0.15–0.73; P = 0.006), major anastomotic leakage (2.1 vs. 5.2%; OR 0.39; 95% CI 0.17–0.87; P = 0.022), and major morbidity (3.5 vs. 6.6% events; OR 0.47; 95% CI 0.24–0.91; P = 0.026). Conclusion: The use of three-row circular staplers independently reduced the risk of anastomotic leakage and related morbidity after left-sided colorectal resection. Twenty-five pati
- Published
- 2023
10. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
- Author
-
Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., Visco C., Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., and Visco C.
- Abstract
COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.
- Published
- 2023
11. Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial–mesenchymal transition pathways
- Author
-
Ottone, T, Silvestrini, G, Piazza, R, Travaglini, S, Gurnari, C, Marchesi, F, Nardozza, A, Fabiani, E, Attardi, E, Guarnera, L, Divona, M, Ricci, P, Irno Consalvo, M, Ienzi, S, Arcese, R, Biagi, A, Fiori, L, Novello, M, Mauriello, A, Venditti, A, Anemona, L, Voso, M, Ottone T., Silvestrini G., Piazza R., Travaglini S., Gurnari C., Marchesi F., Nardozza A. M., Fabiani E., Attardi E., Guarnera L., Divona M., Ricci P., Irno Consalvo M. A., Ienzi S., Arcese R., Biagi A., Fiori L., Novello M., Mauriello A., Venditti A., Anemona L., Voso M. T., Ottone, T, Silvestrini, G, Piazza, R, Travaglini, S, Gurnari, C, Marchesi, F, Nardozza, A, Fabiani, E, Attardi, E, Guarnera, L, Divona, M, Ricci, P, Irno Consalvo, M, Ienzi, S, Arcese, R, Biagi, A, Fiori, L, Novello, M, Mauriello, A, Venditti, A, Anemona, L, Voso, M, Ottone T., Silvestrini G., Piazza R., Travaglini S., Gurnari C., Marchesi F., Nardozza A. M., Fabiani E., Attardi E., Guarnera L., Divona M., Ricci P., Irno Consalvo M. A., Ienzi S., Arcese R., Biagi A., Fiori L., Novello M., Mauriello A., Venditti A., Anemona L., and Voso M. T.
- Abstract
Extramedullary (EM) colonization is a rare complication of acute myeloid leukemia (AML), occurring in about 10% of patients, but the processes underlying tissue invasion are not entirely characterized. Through the application of RNAseq technology, we examined the transcriptome profile of 13 AMLs, 9 of whom presented an EM localization. Our analysis revealed significant deregulation within the extracellular matrix (ECM)-receptor interaction and focal-adhesion pathways, specifically in the EM sites. The transcription factor TWIST1, which is known to impact on cancer invasion by dysregulating epithelial–mesenchymal-transition (EMT) processes, was significantly upregulated in EM-AML. To test the functional impact of TWIST1 overexpression, we treated OCI-AML3s with TWIST1-siRNA or metformin, a drug known to inhibit tumor progression in cancer models. After 48 h, we showed downregulation of TWIST1, and of the EMT-related genes FN1 and SNAI2. This was associated with significant impairment of migration and invasion processes by Boyden chamber assays. Our study shed light on the molecular mechanisms associated with EM tissue invasion in AML, and on the ability of metformin to interfere with key players of this process. TWIST1 may configure as candidate marker of EM-AML progression, and inhibition of EMT-pathways may represent an innovative therapeutic intervention to prevent or treat this complication. [Figure not available: see fulltext.]
- Published
- 2023
12. Immune infiltrating cells in duodenal cancers
- Author
-
Donisi, G., Capretti, G., Cortese, N., Rigamonti, A., Gavazzi, F., Nappo, G., Pulvirenti, A., Sollai, M., Spaggiari, P., Zerbi, A., and Marchesi, F.
- Published
- 2020
- Full Text
- View/download PDF
13. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome
- Author
-
Zacchetti, L, Longhi, L, Bianchi, I, Di Matteo, M, Russo, F, Gandini, L, Manesso, L, Monti, M, Cosentini, R, Di Marco, F, Fagiuoli, S, Grazioli, L, Gritti, P, Previdi, F, Senni, M, Ranieri, M, Lorini, L, Rota, A, Martinelli, A, Pugni, P, Marino, A, Colombo, G, Damiani, M, Ferrari, D, Bonacina, D, Corbella, D, Poli, G, Cantu, D, Ferri, F, Brivio, M, Bonanomi, E, Fabretti, F, Benigni, A, Brambillasca, P, Scarpa, L, Marchesi, F, Zacchetti L., Longhi L., Bianchi I., Di Matteo M., Russo F., Gandini L., Manesso L., Monti M., Cosentini R., Di Marco F., Fagiuoli S., Grazioli L., Gritti P., Previdi F., Senni M., Ranieri M., Lorini L., Rota A., Martinelli A., Pugni P., Marino A., Colombo G., Damiani M., Ferrari D., Bonacina D., Corbella D., Poli G., Cantu D., Ferri F., Brivio M., Bonanomi E., Fabretti F., Benigni A., Brambillasca P., Scarpa L., Marchesi F., Zacchetti, L, Longhi, L, Bianchi, I, Di Matteo, M, Russo, F, Gandini, L, Manesso, L, Monti, M, Cosentini, R, Di Marco, F, Fagiuoli, S, Grazioli, L, Gritti, P, Previdi, F, Senni, M, Ranieri, M, Lorini, L, Rota, A, Martinelli, A, Pugni, P, Marino, A, Colombo, G, Damiani, M, Ferrari, D, Bonacina, D, Corbella, D, Poli, G, Cantu, D, Ferri, F, Brivio, M, Bonanomi, E, Fabretti, F, Benigni, A, Brambillasca, P, Scarpa, L, Marchesi, F, Zacchetti L., Longhi L., Bianchi I., Di Matteo M., Russo F., Gandini L., Manesso L., Monti M., Cosentini R., Di Marco F., Fagiuoli S., Grazioli L., Gritti P., Previdi F., Senni M., Ranieri M., Lorini L., Rota A., Martinelli A., Pugni P., Marino A., Colombo G., Damiani M., Ferrari D., Bonacina D., Corbella D., Poli G., Cantu D., Ferri F., Brivio M., Bonanomi E., Fabretti F., Benigni A., Brambillasca P., Scarpa L., and Marchesi F.
- Abstract
Background: Coronavirus disease 2019-associated acute respiratory distress syndrome (COVID-19 ARDS) seems to differ from the “classic ARDS”, showing initial significant hypoxemia in the face of relatively preserved compliance and evolving later in a scenario of poorly compliant lungs. We tested the hypothesis that in patients with COVID-19 ARDS, the initial value of static compliance of respiratory system (Crs) (1) depends on the previous duration of the disease (i.e., the fewer days of illness, the higher the Crs and vice versa) and (2) identifies different lung patterns of time evolution and response to prone positioning. Methods: This was a single-center prospective observational study. We enrolled consecutive mechanically ventilated patients with a diagnosis of COVID-19 who met ARDS criteria, admitted to intensive care unit (ICU). Patients were divided in four groups based on quartiles of initial Crs. Relationship between Crs and the previous duration of the disease was evaluated. Respiratory parameters collected once a day and during prone positioning were compared between groups. Results: We evaluated 110 mechanically ventilated patients with a diagnosis of COVID-19 who met ARDS criteria admitted to our ICUs. Patients were divided in groups based on quartiles of initial Crs. The median initial Crs was 41 (32–47) ml/cmH2O. No association was found between the previous duration of the disease and the initial Crs. The Crs did not change significantly over time within each quartile. Positive end-expiratory pressure (PEEP) and driving pressure were respectively lower and greater in patients with lower Crs. Prone positioning significantly improved PaO2/FiO2 in the 4 groups, however it increased the Crs significantly only in patients in lower quartile of Crs. Conclusions: In our cohort, the initial Crs is not dependent on the previous duration of COVID-19 disease. Prone positioning improves oxygenation irrespective to initial Crs, but it ameliorates respiratory mecha
- Published
- 2022
14. Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population—on behalf of the Italian Research Group for Gastric Cancer
- Author
-
Lombardi, P, Bernasconi, D, Baiocchi, G, Berselli, M, Biondi, A, Castoro, C, Catarci, M, Degiuli, M, Fumagalli Romario, U, Giacopuzzi, S, Marchesi, F, Marrelli, D, Mazzola, M, Molfino, S, Olmi, S, Rausei, S, Rosa, F, Rosati, R, Roviello, F, Santi, S, Solaini, L, Staderini, F, Vigano, J, Ferrari, G, Agnes, A, Alfieri, S, Alloggio, M, Bencivenga, M, Benedetti, M, Bottari, A, Cianchi, F, Cocozza, E, Dalmonte, G, De Martini, P, De Pascale, S, Desio, M, Emiliani, G, Ercolani, G, Galli, F, Garosio, I, Giani, A, Gualtierotti, M, Marano, L, Morgagni, P, Peri, A, Puccetti, F, Reddavid, R, Uccelli, M, Lombardi P. M., Bernasconi D., Baiocchi G. L., Berselli M., Biondi A., Castoro C., Catarci M., Degiuli M., Fumagalli Romario U., Giacopuzzi S., Marchesi F., Marrelli D., Mazzola M., Molfino S., Olmi S., Rausei S., Rosa F., Rosati R., Roviello F., Santi S., Solaini L., Staderini F., Vigano J., Ferrari G., Agnes A., Alfieri S., Alloggio M., Bencivenga M., Benedetti M., Bottari A., Cianchi F., Cocozza E., Dalmonte G., De Martini P., De Pascale S., Desio M., Emiliani G., Ercolani G., Galli F., Garosio I., Giani A., Gualtierotti M., Marano L., Morgagni P., Peri A., Puccetti F., Reddavid R., Uccelli M., Lombardi, P, Bernasconi, D, Baiocchi, G, Berselli, M, Biondi, A, Castoro, C, Catarci, M, Degiuli, M, Fumagalli Romario, U, Giacopuzzi, S, Marchesi, F, Marrelli, D, Mazzola, M, Molfino, S, Olmi, S, Rausei, S, Rosa, F, Rosati, R, Roviello, F, Santi, S, Solaini, L, Staderini, F, Vigano, J, Ferrari, G, Agnes, A, Alfieri, S, Alloggio, M, Bencivenga, M, Benedetti, M, Bottari, A, Cianchi, F, Cocozza, E, Dalmonte, G, De Martini, P, De Pascale, S, Desio, M, Emiliani, G, Ercolani, G, Galli, F, Garosio, I, Giani, A, Gualtierotti, M, Marano, L, Morgagni, P, Peri, A, Puccetti, F, Reddavid, R, Uccelli, M, Lombardi P. M., Bernasconi D., Baiocchi G. L., Berselli M., Biondi A., Castoro C., Catarci M., Degiuli M., Fumagalli Romario U., Giacopuzzi S., Marchesi F., Marrelli D., Mazzola M., Molfino S., Olmi S., Rausei S., Rosa F., Rosati R., Roviello F., Santi S., Solaini L., Staderini F., Vigano J., Ferrari G., Agnes A., Alfieri S., Alloggio M., Bencivenga M., Benedetti M., Bottari A., Cianchi F., Cocozza E., Dalmonte G., De Martini P., De Pascale S., Desio M., Emiliani G., Ercolani G., Galli F., Garosio I., Giani A., Gualtierotti M., Marano L., Morgagni P., Peri A., Puccetti F., Reddavid R., and Uccelli M.
- Abstract
Background: Oncologic outcomes after laparoscopic gastrectomy for advanced gastric cancer in the West have been poorly investigated. The aim of the present study was to compare survival outcomes in patients undergoing curative-intent laparoscopic and open gastrectomy for advanced gastric cancer in several centres belonging to the Italian Research Group for Gastric Cancer. Methods: Data of patients operated between 2015 and 2018 were retrospectively analysed. Propensity Score Matching was performed to balance baseline characteristics of patients undergoing laparoscopic and open gastrectomy. The primary endpoint was 3-year overall survival. Secondary endpoints were 3-year disease-free survival and short-term outcomes. Multivariable regression analyses for survival were conducted. Results: Data were retrieved from 20 centres. Of the 717 patients included, 438 patients were correctly matched, 219 per group. The 3-year overall survival was 73.6% and 68.7% in the laparoscopic and open group, respectively (p = 0.40). When compared with open gastrectomy, laparoscopic gastrectomy showed comparable 3-year disease-free survival (62.8%, vs 58.9%, p = 0.40), higher rate of return to intended oncologic treatment (56.9% vs 40.2%, p = 0.001), similar 30-day morbidity/mortality. Prognostic factors for survival were ASA Score ≥ 3, age-adjusted Charlson Comorbidity Index ≥ 5, lymph node ratio ≥ 0.15, p/ypTNM Stage III and return to intended oncologic treatment. Conclusions: Laparoscopic gastrectomy for advanced gastric cancer offers similar rates of survival when compared to open gastrectomy, with higher rates of return to intended oncologic treatment. ASA score, age-adjusted Charlson Comorbidity Index, lymph node ratio, return to intended oncologic treatment and p/ypTNM Stage, but not surgical approach, are prognostic factors for survival.
- Published
- 2022
15. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV
- Author
-
Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, 37, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Coviello E, MC, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, 37, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Coviello E, MC, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, and Arcaini L.
- Abstract
The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.
- Published
- 2022
16. Current practice on the use of prophylactic drain after gastrectomy in Italy: the Abdominal Drain in Gastrectomy (ADiGe) survey
- Author
-
Mengardo, V, Weindelmayer, J, Veltri, A, Giacopuzzi, S, Torroni, L, de Manzoni, G, Agresta, F, Alfieri, R, Alfieri, S, Antonacci, N, Baiocchi, G, Bencini, L, Bencivenga, M, Benedetti, M, Berselli, M, Biondi, A, Capolupo, G, Carboni, F, Casadei, R, Casella, F, Catarci, M, Cerri, P, Chiari, D, Cocozza, E, Colombo, G, Cozzaglio, L, Dalmonte, G, Degiuli, M, De Luca, M, De Luca, R, De Manzini, N, De Pasqual, C, De Pascale, S, De Ruvo, N, Di Cosmo, M, Di Leo, A, Di Paola, M, Elio, A, Ferrara, F, Ferrari, G, Fiscon, V, Fumagalli, U, Garulli, G, Gennai, A, Gentile, I, Germani, P, Gualtierotti, M, Guerini, F, Gurrado, A, Inama, M, La Torre, F, Laterza, E, Losurdo, P, Macri, A, Marano, A, Marano, L, Marchesi, F, Marino, F, Massani, M, Menghi, R, Milone, M, Molfino, S, Montuori, M, Moretto, G, Morgagni, P, Morpurgo, E, Abdallah, M, Nespoli, L, Olmi, S, Palaia, R, Pallabazer, G, Parise, P, Pasculli, A, Pericoli Ridolfini, M, Pesce, A, Pinotti, E, Pisano, M, Poiasina, E, Postiglione, V, Rausei, S, Rella, A, Rosa, F, Rosati, R, Rossi, G, Rossit, L, Rovatti, M, Ruspi, L, Sacco, L, Saladino, E, Sansonetti, A, Sartori, A, Scaglione, D, Scaringi, S, Schoenthaler, C, Sena, G, Simone, M, Solaini, L, Strignano, P, Tartaglia, N, Testa, S, Testini, M, Tiberio, G, Treppiedi, E, Vagliasindi, A, Valmasoni, M, Vigano, J, Zanchettin, G, Zanoni, A, Zardini, C, Zerbinati, A, Mengardo V., Weindelmayer J., Veltri A., Giacopuzzi S., Torroni L., de Manzoni G., Agresta F., Alfieri R., Alfieri S., Antonacci N., Baiocchi G. L., Bencini L., Bencivenga M., Benedetti M., Berselli M., Biondi A., Capolupo G. T., Carboni F., Casadei R., Casella F., Catarci M., Cerri P., Chiari D., Cocozza E., Colombo G., Cozzaglio L., Dalmonte G., Degiuli M., De Luca M., De Luca R., De Manzini N., De Pasqual C. A., De Pascale S., De Ruvo N., Di Cosmo M., Di Leo A., Di Paola M., Elio A., Ferrara F., Ferrari G., Fiscon V., Fumagalli U., Garulli G., Gennai A., Gentile I., Germani P., Gualtierotti M., Guerini F., Gurrado A., Inama M., La Torre F., Laterza E., Losurdo P., Macri A., Marano A., Marano L., Marchesi F., Marino F., Massani M., Menghi R., Milone M., Molfino S., Montuori M., Moretto G., Morgagni P., Morpurgo E., Abdallah M., Nespoli L., Olmi S., Palaia R., Pallabazer G., Parise P., Pasculli A., Pericoli Ridolfini M., Pesce A., Pinotti E., Pisano M., Poiasina E., Postiglione V., Rausei S., Rella A., Rosa F., Rosati R., Rossi G., Rossit L., Rovatti M., Ruspi L., Sacco L., Saladino E., Sansonetti A., Sartori A., Scaglione D., Scaringi S., Schoenthaler C., Sena G., Simone M., Solaini L., Strignano P., Tartaglia N., Testa S., Testini M., Tiberio G. A. M., Treppiedi E., Vagliasindi A., Valmasoni M., Vigano J., Zanchettin G., Zanoni A., Zardini C., Zerbinati A., Mengardo, V, Weindelmayer, J, Veltri, A, Giacopuzzi, S, Torroni, L, de Manzoni, G, Agresta, F, Alfieri, R, Alfieri, S, Antonacci, N, Baiocchi, G, Bencini, L, Bencivenga, M, Benedetti, M, Berselli, M, Biondi, A, Capolupo, G, Carboni, F, Casadei, R, Casella, F, Catarci, M, Cerri, P, Chiari, D, Cocozza, E, Colombo, G, Cozzaglio, L, Dalmonte, G, Degiuli, M, De Luca, M, De Luca, R, De Manzini, N, De Pasqual, C, De Pascale, S, De Ruvo, N, Di Cosmo, M, Di Leo, A, Di Paola, M, Elio, A, Ferrara, F, Ferrari, G, Fiscon, V, Fumagalli, U, Garulli, G, Gennai, A, Gentile, I, Germani, P, Gualtierotti, M, Guerini, F, Gurrado, A, Inama, M, La Torre, F, Laterza, E, Losurdo, P, Macri, A, Marano, A, Marano, L, Marchesi, F, Marino, F, Massani, M, Menghi, R, Milone, M, Molfino, S, Montuori, M, Moretto, G, Morgagni, P, Morpurgo, E, Abdallah, M, Nespoli, L, Olmi, S, Palaia, R, Pallabazer, G, Parise, P, Pasculli, A, Pericoli Ridolfini, M, Pesce, A, Pinotti, E, Pisano, M, Poiasina, E, Postiglione, V, Rausei, S, Rella, A, Rosa, F, Rosati, R, Rossi, G, Rossit, L, Rovatti, M, Ruspi, L, Sacco, L, Saladino, E, Sansonetti, A, Sartori, A, Scaglione, D, Scaringi, S, Schoenthaler, C, Sena, G, Simone, M, Solaini, L, Strignano, P, Tartaglia, N, Testa, S, Testini, M, Tiberio, G, Treppiedi, E, Vagliasindi, A, Valmasoni, M, Vigano, J, Zanchettin, G, Zanoni, A, Zardini, C, Zerbinati, A, Mengardo V., Weindelmayer J., Veltri A., Giacopuzzi S., Torroni L., de Manzoni G., Agresta F., Alfieri R., Alfieri S., Antonacci N., Baiocchi G. L., Bencini L., Bencivenga M., Benedetti M., Berselli M., Biondi A., Capolupo G. T., Carboni F., Casadei R., Casella F., Catarci M., Cerri P., Chiari D., Cocozza E., Colombo G., Cozzaglio L., Dalmonte G., Degiuli M., De Luca M., De Luca R., De Manzini N., De Pasqual C. A., De Pascale S., De Ruvo N., Di Cosmo M., Di Leo A., Di Paola M., Elio A., Ferrara F., Ferrari G., Fiscon V., Fumagalli U., Garulli G., Gennai A., Gentile I., Germani P., Gualtierotti M., Guerini F., Gurrado A., Inama M., La Torre F., Laterza E., Losurdo P., Macri A., Marano A., Marano L., Marchesi F., Marino F., Massani M., Menghi R., Milone M., Molfino S., Montuori M., Moretto G., Morgagni P., Morpurgo E., Abdallah M., Nespoli L., Olmi S., Palaia R., Pallabazer G., Parise P., Pasculli A., Pericoli Ridolfini M., Pesce A., Pinotti E., Pisano M., Poiasina E., Postiglione V., Rausei S., Rella A., Rosa F., Rosati R., Rossi G., Rossit L., Rovatti M., Ruspi L., Sacco L., Saladino E., Sansonetti A., Sartori A., Scaglione D., Scaringi S., Schoenthaler C., Sena G., Simone M., Solaini L., Strignano P., Tartaglia N., Testa S., Testini M., Tiberio G. A. M., Treppiedi E., Vagliasindi A., Valmasoni M., Vigano J., Zanchettin G., Zanoni A., Zardini C., and Zerbinati A.
- Abstract
Evidence against the use of prophylactic drain after gastrectomy are increasing and ERAS guidelines suggest the benefit of drain avoidance. Nevertheless, it is unclear whether this practice is still widespread. We conducted a survey among Italian surgeons through the Italian Gastric Cancer Research Group and the Polispecialistic Society of Young Surgeons, aiming to understand the current use of prophylactic drain. A 28-item questionnaire-based survey was developed to analyze the current practice and the individual opinion about the use of prophylactic drain after gastrectomy. Groups based on age, experience and unit volume were separately analyzed. Response of 104 surgeons from 73 surgical units were collected. A standardized ERAS protocol for gastrectomy was applied by 42% of the respondents. Most of the surgeons, regardless of age, experience, or unit volume, declared to routinely place one or more drain after gastrectomy. Only 2 (1.9%) and 7 surgeons (6.7%) belonging to high volume units, do not routinely place drains after total and subtotal gastrectomy, respectively. More than 60% of the participants remove the drain on postoperative day 4–6 after performing an assessment of the anastomosis integrity. Interestingly, less than half of the surgeons believe that drain is the main tool for leak management, and this percentage further drops among younger surgeons. On the other hand, drain’s role seems to be more defined for duodenal stump leak treatment, with almost 50% of the surgeons recognizing its importance. Routine use of prophylactic drain after gastrectomy is still a widespread practice even if younger surgeons are more persuaded that it could not be advantageous.
- Published
- 2022
17. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
- Author
-
Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., Merli F., Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., and Merli F.
- Abstract
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n 5 388) or required hospitalization (n 5 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
- Published
- 2022
18. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant
- Author
-
Marchesi, F., Capria, S., Giannarelli, D., Trisolini, S. M., Ansuinelli, M., Caputo, M. D., Serrao, A., Gumenyuk, S., Renzi, D., Pupo, L., Palombi, F., Provenzano, I., Di Rocco, A., Pisani, F., Romano, A., Spadea, A., Papa, E., Canfora, M., Cantonetti, M., and Mengarelli, A.
- Published
- 2018
- Full Text
- View/download PDF
19. P55 MULTIPLE MYELOMA AND SARS-COV-2 INFECTION: AN EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA) OF 1,221 PATIENTS THROUGH THE DIFFERENT PHASES OF COVID-19 PANDEMIC
- Author
-
Musto, P., primary, Salmanton-García, J., additional, Sgherza, N., additional, Bergantim, R., additional, Farina, F., additional, Glenthøj, A., additional, Seval, G.C., additional, Weinbergerová, B., additional, Bonuomo, V., additional, Bilgin, Y.M., additional, Rahimli, L., additional, Marchesi, F., additional, Cornely, O.A., additional, and Pagano, L., additional
- Published
- 2023
- Full Text
- View/download PDF
20. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
- Author
-
Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G.C., Doesum, J. Van, Jonge, N. de, Bahr, N.C., Maertens, J., Meletiadis, J., Fracchiolla, N.S., Weinbergerová, B., Verga, L., Ráčil, Z., Jiménez, M., Glenthøj, A., Blennow, O., Tanase, A.D., Schönlein, M., Prezioso, L., Khanna, N., Duarte, R.F., Žák, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., Kort, E.A. de, Ribera-Santa Susana, J.M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G.P.M., Nordlander, A., Karlsson, L.K., Hanakova, M., Dragonetti, G., Cabirta, A., Berg Venemyr, C., Gräfe, S., Praet, J. Van, Tragiannidis, A., Petzer, V., López-García, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O.A., Pagano, L., Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G.C., Doesum, J. Van, Jonge, N. de, Bahr, N.C., Maertens, J., Meletiadis, J., Fracchiolla, N.S., Weinbergerová, B., Verga, L., Ráčil, Z., Jiménez, M., Glenthøj, A., Blennow, O., Tanase, A.D., Schönlein, M., Prezioso, L., Khanna, N., Duarte, R.F., Žák, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., Kort, E.A. de, Ribera-Santa Susana, J.M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G.P.M., Nordlander, A., Karlsson, L.K., Hanakova, M., Dragonetti, G., Cabirta, A., Berg Venemyr, C., Gräfe, S., Praet, J. Van, Tragiannidis, A., Petzer, V., López-García, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O.A., and Pagano, L.
- Abstract
Item does not contain fulltext, BACKGROUND: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. METHODS: This multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. RESULTS: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). CONCLUSIONS: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
- Published
- 2023
21. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
- Author
-
Marchesi, F., Salmanton-Garcia, J., Buquicchio, C., Itri, F., Besson, C., Davila-Valls, J., Martin-Perez, S., Fianchi, Luana, Rahimli, L., Tarantini, G., Grifoni, F. I., Sciume, M., Labrador, J., Cordoba, R., Lopez-Garcia, A., Fracchiolla, N. S., Farina, F., Ammatuna, E., Cingolani, Antonella, Garcia-Bordallo, D., Grafe, S. K., Bilgin, Y. M., Dargenio, M., Gonzalez-Lopez, T. J., Guidetti, A., Lahmer, T., Lavilla-Rubira, E., Mendez, G. -A., Prezioso, L., Schonlein, M., Van Doesum, J., Wolf, D., Hersby, D. S., Magyari, F., Van Praet, J., Petzer, V., Tascini, C., Falces-Romero, I., Glenthoj, A., Cornely, O. A., Pagano, Livio, Fianchi L., Cingolani A. (ORCID:0000-0002-3793-2755), Pagano L. (ORCID:0000-0001-8287-928X), Marchesi, F., Salmanton-Garcia, J., Buquicchio, C., Itri, F., Besson, C., Davila-Valls, J., Martin-Perez, S., Fianchi, Luana, Rahimli, L., Tarantini, G., Grifoni, F. I., Sciume, M., Labrador, J., Cordoba, R., Lopez-Garcia, A., Fracchiolla, N. S., Farina, F., Ammatuna, E., Cingolani, Antonella, Garcia-Bordallo, D., Grafe, S. K., Bilgin, Y. M., Dargenio, M., Gonzalez-Lopez, T. J., Guidetti, A., Lahmer, T., Lavilla-Rubira, E., Mendez, G. -A., Prezioso, L., Schonlein, M., Van Doesum, J., Wolf, D., Hersby, D. S., Magyari, F., Van Praet, J., Petzer, V., Tascini, C., Falces-Romero, I., Glenthoj, A., Cornely, O. A., Pagano, Livio, Fianchi L., Cingolani A. (ORCID:0000-0002-3793-2755), and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
- Published
- 2023
22. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
- Author
-
Salmanton-Garcia, J., Marchesi, F., Gomes da Silva, M., Farina, F., Davila-Valls, J., Bilgin, Y. M., Glenthoj, A., Falces-Romero, I., Van Doesum, J., Labrador, J., Buquicchio, C., El-Ashwah, S., Petzer, V., Van Praet, J., Schonlein, M., Dargenio, M., Mendez, G. -A., Meers, S., Itri, F., Giordano, A., Pinczes, L. I., Espigado, I., Stojanoski, Z., Lopez-Garcia, A., Prezioso, L., Jaksic, O., Vena, A., Fracchiolla, N. S., Gonzalez-Lopez, T. J., Colovic, N., Delia, M., Weinbergerova, B., Marchetti, M., Marques de Almeida, J., Finizio, O., Besson, C., Biernat, M. M., Valkovic, T., Lahmer, T., Cuccaro, A., Ormazabal-Velez, I., Batinic, J., Fernandez, N., De Jonge, N., Tascini, C., Anastasopoulou, A. N., Dulery, R., Del Principe, M. I., Plantefeve, G., Papa, M. V., Nucci, M., Jimenez, M., Aujayeb, A., Hernandez-Rivas, J. -A., Merelli, M., Cattaneo, C., Blennow, O., Nordlander, A., Cabirta, A., Varricchio, G., Sacchi, M. V., Cordoba, R., Arellano, E., Grafe, S. K., Wolf, D., Emarah, Z., Ammatuna, E., Hersby, D. S., Martin-Perez, S., Nunes Rodrigues, R., Rahimli, L., Pagano, Livio, Cornely, O. A., Piukovics, K., De Ramon, C., Danion, F., Yahya, A., Guidetti, A., Garcia-Vidal, C., Sili, U., Meletiadis, J., De Kort, E., Verga, L., Serrano, L., Erben, N., Di Blasi, R., Tragiannidis, A., Ribera-Santa Susana, J. -M., Ommen, H. -B., Busca, A., Coppola, N., Bergantim, R., Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, A., Mikulska, M., Machado, M., Shan Kho, C., Hassan, N., Gavriilaki, E., Cordini, G., Chi, L. Y. A., Eggerer, M., Hoenigl, M., Prattes, J., Jimenez-Lorenzo, M. -J., Zompi, S., Zambrotta, G. P. M., Colak, G. M., Garcia-Pouton, N., Aiello, T. F., Prin, R., Stamouli, M., Samarkos, M., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Criscuolo M., Fianchi L., Bonanni M., Salmanton-Garcia, J., Marchesi, F., Gomes da Silva, M., Farina, F., Davila-Valls, J., Bilgin, Y. M., Glenthoj, A., Falces-Romero, I., Van Doesum, J., Labrador, J., Buquicchio, C., El-Ashwah, S., Petzer, V., Van Praet, J., Schonlein, M., Dargenio, M., Mendez, G. -A., Meers, S., Itri, F., Giordano, A., Pinczes, L. I., Espigado, I., Stojanoski, Z., Lopez-Garcia, A., Prezioso, L., Jaksic, O., Vena, A., Fracchiolla, N. S., Gonzalez-Lopez, T. J., Colovic, N., Delia, M., Weinbergerova, B., Marchetti, M., Marques de Almeida, J., Finizio, O., Besson, C., Biernat, M. M., Valkovic, T., Lahmer, T., Cuccaro, A., Ormazabal-Velez, I., Batinic, J., Fernandez, N., De Jonge, N., Tascini, C., Anastasopoulou, A. N., Dulery, R., Del Principe, M. I., Plantefeve, G., Papa, M. V., Nucci, M., Jimenez, M., Aujayeb, A., Hernandez-Rivas, J. -A., Merelli, M., Cattaneo, C., Blennow, O., Nordlander, A., Cabirta, A., Varricchio, G., Sacchi, M. V., Cordoba, R., Arellano, E., Grafe, S. K., Wolf, D., Emarah, Z., Ammatuna, E., Hersby, D. S., Martin-Perez, S., Nunes Rodrigues, R., Rahimli, L., Pagano, Livio, Cornely, O. A., Piukovics, K., De Ramon, C., Danion, F., Yahya, A., Guidetti, A., Garcia-Vidal, C., Sili, U., Meletiadis, J., De Kort, E., Verga, L., Serrano, L., Erben, N., Di Blasi, R., Tragiannidis, A., Ribera-Santa Susana, J. -M., Ommen, H. -B., Busca, A., Coppola, N., Bergantim, R., Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, A., Mikulska, M., Machado, M., Shan Kho, C., Hassan, N., Gavriilaki, E., Cordini, G., Chi, L. Y. A., Eggerer, M., Hoenigl, M., Prattes, J., Jimenez-Lorenzo, M. -J., Zompi, S., Zambrotta, G. P. M., Colak, G. M., Garcia-Pouton, N., Aiello, T. F., Prin, R., Stamouli, M., Samarkos, M., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Criscuolo M., Fianchi L., and Bonanni M.
- Abstract
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mort
- Published
- 2023
23. A national survey on the current status of minimally invasive gastric practice on behalf of GIRCG
- Author
-
Milone, M, D'Amore, A, Alfieri, S, Ambrosio, M, Andreuccetti, J, Ansaloni, L, Antonucci, A, Arganini, M, Baiocchi, G, Barone, M, Bencini, L, Bencivenga, M, Boccia, L, Boni, L, Braga, M, Cianchi, F, Cipollari, C, Contine, A, Cotsoglou, C, D'Imporzano, S, De Manzoni, G, De Pascale, S, De Ruvo, N, Degiuli, M, Donini, A, Elmore, U, Ercolani, G, Ferrari, G, Fumagalli, R, Garulli, G, Gelmini, R, Graziosi, L, Gualtierotti, M, Guglielmi, A, Inama, M, Maffeis, F, Maione, F, Manigrasso, M, Marchesi, F, Marrelli, D, Massobrio, A, Moretto, G, Moukachar, A, Navarra, G, Nigri, G, Olmi, S, Palaia, R, Papis, D, Parise, P, Pedrazzani, C, Petri, R, Pignata, G, Pisano, M, Rausei, S, Reddavid, R, Rocco, G, Rosa, F, Rosati, R, Rossit, L, Rottoli, M, Roviello, F, Santi, S, Scabini, S, Scaringi, S, Solaini, L, Staderini, F, Taglietti, L, Torre, B, Ubiali, P, Uccelli, M, Uggeri, F, Vertaldi, S, Viganò, J, De Palma, G, Giacopuzzi, S, Milone, Marco, D'Amore, Anna, Alfieri, Sergio, Ambrosio, Maria Raffaella, Andreuccetti, Jacopo, Ansaloni, Luca, Antonucci, Adelmo, Arganini, Marco, Baiocchi, Gianluca, Barone, Mirko, Bencini, Lapo, Bencivenga, Maria, Boccia, Luigi, Boni, Luigi, Braga, Marco, Cianchi, Fabio, Cipollari, Chiara, Contine, Alessandro, Cotsoglou, Christian, D'Imporzano, Simone, De Manzoni, Giovanni, De Pascale, Stefano, De Ruvo, Nicola, Degiuli, Maurizio, Donini, Annibale, Elmore, Ugo, Ercolani, Giorgio, Ferrari, Giovanni, Fumagalli, Romario Uberto, Garulli, Gianluca, Gelmini, Roberta, Graziosi, Luigina, Gualtierotti, Monica, Guglielmi, Alfredo, Inama, Marco, Maffeis, Federica, Maione, Francesco, Manigrasso, Michele, Marchesi, Federico, Marrelli, Daniele, Massobrio, Andrea, Moretto, Gianluigi, Moukachar, Aballah, Navarra, Giuseppe, Nigri, Giuseppe, Olmi, Stefano, Palaia, Raffaele, Papis, Davide, Parise, Paolo, Pedrazzani, Corrado, Petri, Roberto, Pignata, Giusto, Pisano, Michele, Rausei, Stefano, Reddavid, Rossella, Rocco, Giuseppe, Rosa, Fausto, Rosati, Riccardo, Rossit, Luca, Rottoli, Matteo, Roviello, Franco, Santi, Stefano, Scabini, Stefano, Scaringi, Stefano, Solaini, Leonardo, Staderini, Fabio, Taglietti, Lucio, Torre, Beatrice, Ubiali, Paolo, Uccelli, Matteo, Uggeri, Fabio, Vertaldi, Sara, Viganò, Jacopo, De Palma, Giovanni Domenico, Giacopuzzi, Simone, Milone, M, D'Amore, A, Alfieri, S, Ambrosio, M, Andreuccetti, J, Ansaloni, L, Antonucci, A, Arganini, M, Baiocchi, G, Barone, M, Bencini, L, Bencivenga, M, Boccia, L, Boni, L, Braga, M, Cianchi, F, Cipollari, C, Contine, A, Cotsoglou, C, D'Imporzano, S, De Manzoni, G, De Pascale, S, De Ruvo, N, Degiuli, M, Donini, A, Elmore, U, Ercolani, G, Ferrari, G, Fumagalli, R, Garulli, G, Gelmini, R, Graziosi, L, Gualtierotti, M, Guglielmi, A, Inama, M, Maffeis, F, Maione, F, Manigrasso, M, Marchesi, F, Marrelli, D, Massobrio, A, Moretto, G, Moukachar, A, Navarra, G, Nigri, G, Olmi, S, Palaia, R, Papis, D, Parise, P, Pedrazzani, C, Petri, R, Pignata, G, Pisano, M, Rausei, S, Reddavid, R, Rocco, G, Rosa, F, Rosati, R, Rossit, L, Rottoli, M, Roviello, F, Santi, S, Scabini, S, Scaringi, S, Solaini, L, Staderini, F, Taglietti, L, Torre, B, Ubiali, P, Uccelli, M, Uggeri, F, Vertaldi, S, Viganò, J, De Palma, G, Giacopuzzi, S, Milone, Marco, D'Amore, Anna, Alfieri, Sergio, Ambrosio, Maria Raffaella, Andreuccetti, Jacopo, Ansaloni, Luca, Antonucci, Adelmo, Arganini, Marco, Baiocchi, Gianluca, Barone, Mirko, Bencini, Lapo, Bencivenga, Maria, Boccia, Luigi, Boni, Luigi, Braga, Marco, Cianchi, Fabio, Cipollari, Chiara, Contine, Alessandro, Cotsoglou, Christian, D'Imporzano, Simone, De Manzoni, Giovanni, De Pascale, Stefano, De Ruvo, Nicola, Degiuli, Maurizio, Donini, Annibale, Elmore, Ugo, Ercolani, Giorgio, Ferrari, Giovanni, Fumagalli, Romario Uberto, Garulli, Gianluca, Gelmini, Roberta, Graziosi, Luigina, Gualtierotti, Monica, Guglielmi, Alfredo, Inama, Marco, Maffeis, Federica, Maione, Francesco, Manigrasso, Michele, Marchesi, Federico, Marrelli, Daniele, Massobrio, Andrea, Moretto, Gianluigi, Moukachar, Aballah, Navarra, Giuseppe, Nigri, Giuseppe, Olmi, Stefano, Palaia, Raffaele, Papis, Davide, Parise, Paolo, Pedrazzani, Corrado, Petri, Roberto, Pignata, Giusto, Pisano, Michele, Rausei, Stefano, Reddavid, Rossella, Rocco, Giuseppe, Rosa, Fausto, Rosati, Riccardo, Rossit, Luca, Rottoli, Matteo, Roviello, Franco, Santi, Stefano, Scabini, Stefano, Scaringi, Stefano, Solaini, Leonardo, Staderini, Fabio, Taglietti, Lucio, Torre, Beatrice, Ubiali, Paolo, Uccelli, Matteo, Uggeri, Fabio, Vertaldi, Sara, Viganò, Jacopo, De Palma, Giovanni Domenico, and Giacopuzzi, Simone
- Abstract
Italian Research Group for Gastric Cancer (GIRCG), during the 2013 annual Consensus Conference to gastric cancer, stated that laparoscopic or robotic approach should be limited only to early gastric cancer (EGC) and no further guidelines were currently available. However, accumulated evidences, mainly from eastern experiences, have supported the application of minimally invasive surgery also for locally advanced gastric cancer (AGC). The aim of our study is to give a snapshot of current surgical propensity of expert Italian upper gastrointestinal surgeons in performing minimally invasive techniques for the treatment of gastric cancer in order to answer to the question if clinical practice overcome the recommendation. Experts in the field among the Italian Research Group for Gastric Cancer (GIRCG) were invited to join a web 30-item survey through a formal e-mail from January 1st, 2020, to June 31st, 2020. Responses were collected from 46 participants out of 100 upper gastrointestinal surgeons. Percentage of surgeons choosing a minimally invasive approach to treat early and advanced gastric cancer was similar. Additionally analyzing data from the centers involved, we obtained that the percentage of minimally invasive total and partial gastrectomies in advanced cases augmented with the increase of surgical procedures performed per year (p=0.02 and p=0.04 respectively). It is reasonable to assume that there is a widening of indications given by the current national guideline into clinical practice. Propensity of expert Italian upper gastrointestinal surgeons was to perform minimally invasive surgery not only for early but also for advanced gastric cancer. Of interest volume activity correlated with the propensity of surgeons to select a minimally invasive approach.
- Published
- 2023
24. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
- Author
-
Del Principe, M. I., Seidel, D., Criscuolo, Marianna, Dargenio, M., Racil, Z., Piedimonte, M., Marchesi, F., Nadali, G., Koehler, P., Fracchiolla, N., Cattaneo, C., Klimko, N., Spolzino, A., Yilmaz Karapinar, D., Demiraslan, H., Duarte, R. F., Demeter, J., Stanzani, M., Melillo, L. M. A., Basilico, C., Cesaro, S., Paterno, G., Califano, C., Delia, M., Buzzatti, E., Busca, A., Alakel, N., Arsenijevi'C, V. A., Camus, V., Falces-Romero, I., Itzhak, L., Kouba, M., Martino, R., Sedlacek, P., Weinbergerova, B., Cornely, O. A., Pagano, Livio, Criscuolo M., Pagano L. (ORCID:0000-0001-8287-928X), Del Principe, M. I., Seidel, D., Criscuolo, Marianna, Dargenio, M., Racil, Z., Piedimonte, M., Marchesi, F., Nadali, G., Koehler, P., Fracchiolla, N., Cattaneo, C., Klimko, N., Spolzino, A., Yilmaz Karapinar, D., Demiraslan, H., Duarte, R. F., Demeter, J., Stanzani, M., Melillo, L. M. A., Basilico, C., Cesaro, S., Paterno, G., Califano, C., Delia, M., Buzzatti, E., Busca, A., Alakel, N., Arsenijevi'C, V. A., Camus, V., Falces-Romero, I., Itzhak, L., Kouba, M., Martino, R., Sedlacek, P., Weinbergerova, B., Cornely, O. A., Pagano, Livio, Criscuolo M., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Background: Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods: HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results: Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2–78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p <.0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p =.001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396–5.204, p =.003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151–4.376, p =.018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102–7.601, p <.001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192–5.222, p =.015). Conclusions: Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.
- Published
- 2023
25. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
- Author
-
Salmanton-Garcia, J., Marchesi, F., Koehler, P., Weinbergerova, B., Colovic, N., Falces-Romero, I., Buquicchio, C., Farina, F., van Praet, J., Biernat, M. M., Itri, F., Prezioso, L., Tascini, C., Vena, A., Romano, A., Delia, M., Davila-Valls, J., Martin-Perez, S., Lavilla-Rubira, E., Adzic-vukicevic, T., Garcia-Bordallo, D., Lopez-Garcia, A., Criscuolo, Marianna, Petzer, V., Fracchiolla, N. S., Espigado, I., Sili, U., Meers, S., Erben, N., Cattaneo, C., Tragiannidis, A., Gavriilaki, E., Schonlein, M., Mitrovic, M., Pantic, N., Merelli, M., Labrador, J., Hernandez-Rivas, J. -A., Glenthoj, A., Fouquet, G., del Principe, M. I., Dargenio, M., Calbacho, M., Besson, C., Kohn, M., Grafe, S., Hersby, D. S., Arellano, E., Colak, G. M., Wolf, D., Marchetti, M., Nordlander, A., Blennow, O., Cordoba, R., Miskovic, B., Mladenovic, M., Bavastro, M., Limongelli, A., Rahimli, L., Pagano, Livio, Cornely, O. A., Criscuolo M., Pagano L. (ORCID:0000-0001-8287-928X), Salmanton-Garcia, J., Marchesi, F., Koehler, P., Weinbergerova, B., Colovic, N., Falces-Romero, I., Buquicchio, C., Farina, F., van Praet, J., Biernat, M. M., Itri, F., Prezioso, L., Tascini, C., Vena, A., Romano, A., Delia, M., Davila-Valls, J., Martin-Perez, S., Lavilla-Rubira, E., Adzic-vukicevic, T., Garcia-Bordallo, D., Lopez-Garcia, A., Criscuolo, Marianna, Petzer, V., Fracchiolla, N. S., Espigado, I., Sili, U., Meers, S., Erben, N., Cattaneo, C., Tragiannidis, A., Gavriilaki, E., Schonlein, M., Mitrovic, M., Pantic, N., Merelli, M., Labrador, J., Hernandez-Rivas, J. -A., Glenthoj, A., Fouquet, G., del Principe, M. I., Dargenio, M., Calbacho, M., Besson, C., Kohn, M., Grafe, S., Hersby, D. S., Arellano, E., Colak, G. M., Wolf, D., Marchetti, M., Nordlander, A., Blennow, O., Cordoba, R., Miskovic, B., Mladenovic, M., Bavastro, M., Limongelli, A., Rahimli, L., Pagano, Livio, Cornely, O. A., Criscuolo M., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications. A caveat for molnupiravir is the mode of action induces viral mutations. Mortality rate reduction with molnupiravir was less pronounced than that with nirmatrelvir/ritonavir in patients without haematological malignancy. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, molnupiravir and nirmatrelvir/ritonavir were compared in a cohort of patients with haematological malignancies. Methods: Clinical data from patients treated with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and severity of baseline haematological malignancy to controls treated with nirmatrelvir/ritonavir. Results: A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (interquartile range [IQR] 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 56.9% (n=66) of the patients had controlled baseline haematological malignancy, 12.9% (n=15) had stable disease, and 30.2% (n=35) had active disease at COVID-19 onset in each group. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of patients in the two groups were vaccina
- Published
- 2023
26. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey
- Author
-
Trecarichi, Enrico Maria, Giuliano, G., Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Bonuomo, V., Busca, A., Principe, M. I. D., Daffini, R., Simonetti, E., Dragonetti, Giulia, Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Tumbarello M. (ORCID:0000-0002-9519-8552), Trecarichi, Enrico Maria, Giuliano, G., Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Bonuomo, V., Busca, A., Principe, M. I. D., Daffini, R., Simonetti, E., Dragonetti, Giulia, Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), and Tumbarello M. (ORCID:0000-0002-9519-8552)
- Abstract
Bloodstream infections (BSI) caused by Gram-negative bacteria (GNB) in patients with hematological malignancies (HM) have been associated with high mortality rates, particularly with infections caused by antibiotic-resistant strains. A multicenter cohort study including all consecutive episodes of GNB BSI in HM patients was conducted to update the epidemiology and antibiotic resistance patterns (compared to our previous survey conducted between 2009 and 2012) and investigate risk factors for GNB BSI due to multidrug-resistant (MDR) isolates. A total of 834 GNB were recovered in 811 BSI episodes from January 2016 to December 2018. Compared to the previous survey, there was a significant reduction in use of fluoroquinolone prophylaxis and a significant recovery in susceptibility rates to ciprofloxacin among Pseudomonas aeruginosa, Escherichia coli and Enterobacter cloacae isolates. In addition, there was a shift to a significantly increased susceptibility of P. aeruginosa isolates to ceftazidime, meropenem, and gentamicin. A total of 256/834 (30.7%) isolates were MDR. In multivariable analysis, MDR bacteria culture-positive surveillance rectal swabs, previous therapy with aminoglycosides and carbapenems, fluoroquinolone prophylaxis, and time at risk were independently associated with MDR GNB BSI. In conclusion, despite the persistence of a high prevalence of MDR GNB, there was a shift to a reduced use of fluoroquinolone prophylaxis and increased rates of susceptibility to fluoroquinolones in almost all isolates and to almost all antibiotics tested among P. aeruginosa isolates, compared to our previous survey. Fluoroquinolone prophylaxis and previous rectal colonization by MDR bacteria were independent risk factors for MDR GNB BSI in the present study.
- Published
- 2023
27. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
- Author
-
Cesaro, S., Mikulska, M., Hirsch, H. H., Styczynski, J., Meylan, S., Cordonnier, C., Navarro, D., von Lilienfeld-Toal, M., Mehra, V., Marchesi, F., Besson, C., Masculano, R. C., Beutel, G., Einsele, H., Maertens, J., de la Camara, R., Ljungman, P., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), Cesaro, S., Mikulska, M., Hirsch, H. H., Styczynski, J., Meylan, S., Cordonnier, C., Navarro, D., von Lilienfeld-Toal, M., Mehra, V., Marchesi, F., Besson, C., Masculano, R. C., Beutel, G., Einsele, H., Maertens, J., de la Camara, R., Ljungman, P., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
N/A
- Published
- 2023
28. SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
- Author
-
Criscuolo, Marianna, Salmanton-Garcia, J., Fracchiolla, N., Dragonetti, Giulia, Khanna, N., Weinbergerova, B., Schonlein, M., Machado, M., Labrador, J., Kolditz, M., Itri, F., Gomes Da Silva, M., Bonuomo, V., Sciume, M., Nunes Rodrigues, R., Grafe, S., Marchesi, F., Cornely, O. A., Pagano, Livio, Criscuolo M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Criscuolo, Marianna, Salmanton-Garcia, J., Fracchiolla, N., Dragonetti, Giulia, Khanna, N., Weinbergerova, B., Schonlein, M., Machado, M., Labrador, J., Kolditz, M., Itri, F., Gomes Da Silva, M., Bonuomo, V., Sciume, M., Nunes Rodrigues, R., Grafe, S., Marchesi, F., Cornely, O. A., Pagano, Livio, Criscuolo M., Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
N/A
- Published
- 2023
29. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
- Author
-
van Doesum, J. A., Salmanton-Garcia, J., Marchesi, F., Blasi, R. D., Falces-Romero, I., Cabirta, A., Farina, F., Besson, C., Weinbergerova, B., Van Praet, J., Schonlein, M., Lopez-Garcia, A., Lamure, S., Guidetti, A., De Ramon-Sanchez, C., Batinic, J., Gavriilaki, E., Tragiannidis, A., Tisi, M. C., Plantefeve, G., Petzer, V., Ormazabal-Velez, I., Almeida, J. M. D., Marchetti, M., Maertens, J., Machado, M., Kulasekararaj, A., Hernandez-Rivas, J. -A., Silva, M. G. D., Fernandez, N., Espigado, I., Drgona, L., Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, M., Blennow, O., Wolf, D., van Anrooij, B., Rodrigues, R. N., Nordlander, A., Martin-Gonzalez, J. -A., Lievin, R., Jimenez, M., Grafe, S. K., Garcia-Sanz, R., Cordoba, R., Rahimli, L., van Meerten, T., Cornely, O. A., Pagano, Livio, Dragonetti G., Metafuni E., Pagano L. (ORCID:0000-0001-8287-928X), van Doesum, J. A., Salmanton-Garcia, J., Marchesi, F., Blasi, R. D., Falces-Romero, I., Cabirta, A., Farina, F., Besson, C., Weinbergerova, B., Van Praet, J., Schonlein, M., Lopez-Garcia, A., Lamure, S., Guidetti, A., De Ramon-Sanchez, C., Batinic, J., Gavriilaki, E., Tragiannidis, A., Tisi, M. C., Plantefeve, G., Petzer, V., Ormazabal-Velez, I., Almeida, J. M. D., Marchetti, M., Maertens, J., Machado, M., Kulasekararaj, A., Hernandez-Rivas, J. -A., Silva, M. G. D., Fernandez, N., Espigado, I., Drgona, L., Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, M., Blennow, O., Wolf, D., van Anrooij, B., Rodrigues, R. N., Nordlander, A., Martin-Gonzalez, J. -A., Lievin, R., Jimenez, M., Grafe, S. K., Garcia-Sanz, R., Cordoba, R., Rahimli, L., van Meerten, T., Cornely, O. A., Pagano, Livio, Dragonetti G., Metafuni E., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
- Published
- 2023
30. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
- Author
-
Fianchi, Luana, Guolo, F., Marchesi, F., Cattaneo, C., Gottardi, M., Restuccia, F., Candoni, A., Ortu La Barbera, E., Fazzi, R., Pasciolla, C., Finizio, O., Fracchiolla, N., Delia, M., Lessi, F., Dargenio, M., Bonuomo, V., Del Principe, M. I., Zappasodi, P., Picardi, M., Basilico, C., Piedimonte, M., Minetto, P., Giordano, A., Chiusolo, Patrizia, Prezioso, L., Buquicchio, C., Melillo, L. M. A., Zama, D., Farina, F., Mancini, V., Terrenato, I., Rondoni, M., Urbino, I., Tumbarello, Mario, Busca, A., Pagano, Livio, Fianchi L., Chiusolo P. (ORCID:0000-0002-1355-1587), Tumbarello M. (ORCID:0000-0002-9519-8552), Pagano L. (ORCID:0000-0001-8287-928X), Fianchi, Luana, Guolo, F., Marchesi, F., Cattaneo, C., Gottardi, M., Restuccia, F., Candoni, A., Ortu La Barbera, E., Fazzi, R., Pasciolla, C., Finizio, O., Fracchiolla, N., Delia, M., Lessi, F., Dargenio, M., Bonuomo, V., Del Principe, M. I., Zappasodi, P., Picardi, M., Basilico, C., Piedimonte, M., Minetto, P., Giordano, A., Chiusolo, Patrizia, Prezioso, L., Buquicchio, C., Melillo, L. M. A., Zama, D., Farina, F., Mancini, V., Terrenato, I., Rondoni, M., Urbino, I., Tumbarello, Mario, Busca, A., Pagano, Livio, Fianchi L., Chiusolo P. (ORCID:0000-0002-1355-1587), Tumbarello M. (ORCID:0000-0002-9519-8552), and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
In the present study, we aimed to evaluate the absolute risk of infection in the real-life setting of AML patients treated with CPX-351. The study included all patients with AML from 30 Italian hematology centers of the SEIFEM group who received CPX-351 from July 2018 to June 2021. There were 200 patients included. Overall, 336 CPX-351 courses were counted: all 200 patients received the first induction cycle, 18 patients (5%) received a second CPX-351 induction, while 86 patients (26%) proceeded with the first CPX-351 consolidation cycle, and 32 patients (10%) received a second CPX-351 consolidation. A total of 249 febrile events were recorded: 193 during the first or second induction, and 56 after the first or second consolidation. After the diagnostic work-up, 92 events (37%) were classified as febrile neutropenia of unknown origin (FUO), 118 (47%) were classifiable as microbiologically documented infections, and 39 (17%) were classifiable as clinically documented infections. The overall 30-day mortality rate was 14% (28/200). The attributable mortality–infection rate was 6% (15/249). A lack of response to the CPX-351 treatment was the only factor significantly associated with mortality in the multivariate analysis [p-value: 0.004, OR 0.05, 95% CI 0.01–0.39]. Our study confirms the good safety profile of CPX-351 in a real-life setting, with an incidence of infectious complications comparable to that of the pivotal studies; despite prolonged neutropenia, the incidence of fungal infections was low, as was infection-related mortality.
- Published
- 2023
31. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
- Author
-
Rossi, G., Salmanton-Garcia, J., Cattaneo, C., Marchesi, F., Davila-Valls, J., Martin-Perez, S., Itri, F., Lopez-Garcia, A., Glenthoj, A., Da Silva, M. G., Besson, C., Marchetti, M., Weinbergerova, B., Jaksic, O., Jimenez, M., Bilgin, Y. M., Van Doesum, J., Farina, F., Ak, P., Verga, L., Collins, G. P., Bonuomo, V., Praet, J. V., Nucci, M., Meers, S., Espigado, I., Fracchiolla, N. S., Valkovic, T., Poulsen, C. B., Colovic, N., Dragonetti, Giulia, Ledoux, M. -P., Tascini, C., Buquicchio, C., Blennow, O., Passamonti, F., Machado, M., Labrador, J., Duarte, R. F., Schonlein, M., Prezioso, L., Falces-Romero, I., Kulasekararaj, A., Garcia-Vidal, C., Fernandez, N., Abu-Zeinah, G., Ormazabal-Velez, I., Ad ic-Vukicevic, T., Piukovics, K., Stoma, I., Cuccaro, A., Magliano, G., Szotkowski, T., Gonzalez-Lopez, T. -J., El-Ashwah, S., Bergantim, R., Sili, U., Maertens, J., Demirkan, F., De Ramon, C., Petzer, V., Del Principe, M. I., Navratil, M., Dargenio, M., Seval, G. C., Samarkos, M., Racil, Z., Pinczes, L. I., Lahmer, T., Busca, A., Mendez, G. -A., Vena, A., Biernat, M. M., Merelli, M., Calbacho, M., Barac, A., Bavastro, M., Limongelli, A., Ilhan, O., Wolf, D., Colak, G. M., Garcia-Sanz, R., Emarah, Z., Mi kovic, B., Grafe, S. K., Mladenovic, M., Aiello, T. F., Nunez-Martin-Buitrago, L., Nordlander, A., Arellano, E., Zambrotta, G. P. M., Ammatuna, E., Cabirta, A., Sacchi, M. V., Rodrigues, R. N., Hersby, D. S., Hanakova, M., Rahimli, L., Cordoba, R., Cornely, O. A., Pagano, Livio, Marques De, Almeida, Hernandez-Rivas, Marques De Almeida, J., Hernandez-Rivas, J. A., Guidetti, A., Finizio, O., Stojanoski, Z., Cvetanoski, M., Meletiadis, J., De Jonge, N., Antic, D., Ali, N., Tisi, M. C., Serrano, L., Plantefeve, G., Khanna, N., Hoenigl, M., Cernan, M., Miranda-Castillo, C., Fernandez-Galan, M., Serris, A., Erben, N., Dulery, R., Aujayeb, A., Papa, M. V., Novak, J., Delia, M., Sapienza, G., Reizine, F., Omrani, A. S., Di Blasi, R., Lamure, S., Drgona, L., Coppola, N., Batinic, J., Al-Khabori, M., Ribera-Santa Susana, J. -M., Piedimonte, M., Loureiro-Amigo, J., Fouquet, G., Fazzi, R., Danion, F., Schubert, J., Hoell-Neugebauer, B., Bahr, N. C., Yahia, A. O., Torres-Atienza, A., Rinaldi, I., Popova, M., Ommen, H. -B., Mitra, M. E., Mikulska, M., Lacej, I., Khostelidi, S., Win, S., Vinh, D., Saleh, M., Prattes, J., Jindra, P., Guolo, F., Della Pepa, R., Chelysheva, E., Zdziarski, P., Wai-Man, V., Soto-Silva, A., Orth, H. M., Malak, S., Lorenzo De La Pena, L., Kolditz, M., Kho, C. S., Heath, C. H., Groh, A., Gavriilaki, E., Fung, M., Egger, M., De Kort, E., De Cabo, E., Cushion, T., Chowdhury, F. R., Ceesay, M. M., Brehon, M., Varricchio, G., Tafuri, A., Jimenez-Lorenzo, M. -J., Klimko, N., Tsirigotis, P., Antoniadou, A., Vehreschild, M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Rossi, G., Salmanton-Garcia, J., Cattaneo, C., Marchesi, F., Davila-Valls, J., Martin-Perez, S., Itri, F., Lopez-Garcia, A., Glenthoj, A., Da Silva, M. G., Besson, C., Marchetti, M., Weinbergerova, B., Jaksic, O., Jimenez, M., Bilgin, Y. M., Van Doesum, J., Farina, F., Ak, P., Verga, L., Collins, G. P., Bonuomo, V., Praet, J. V., Nucci, M., Meers, S., Espigado, I., Fracchiolla, N. S., Valkovic, T., Poulsen, C. B., Colovic, N., Dragonetti, Giulia, Ledoux, M. -P., Tascini, C., Buquicchio, C., Blennow, O., Passamonti, F., Machado, M., Labrador, J., Duarte, R. F., Schonlein, M., Prezioso, L., Falces-Romero, I., Kulasekararaj, A., Garcia-Vidal, C., Fernandez, N., Abu-Zeinah, G., Ormazabal-Velez, I., Ad ic-Vukicevic, T., Piukovics, K., Stoma, I., Cuccaro, A., Magliano, G., Szotkowski, T., Gonzalez-Lopez, T. -J., El-Ashwah, S., Bergantim, R., Sili, U., Maertens, J., Demirkan, F., De Ramon, C., Petzer, V., Del Principe, M. I., Navratil, M., Dargenio, M., Seval, G. C., Samarkos, M., Racil, Z., Pinczes, L. I., Lahmer, T., Busca, A., Mendez, G. -A., Vena, A., Biernat, M. M., Merelli, M., Calbacho, M., Barac, A., Bavastro, M., Limongelli, A., Ilhan, O., Wolf, D., Colak, G. M., Garcia-Sanz, R., Emarah, Z., Mi kovic, B., Grafe, S. K., Mladenovic, M., Aiello, T. F., Nunez-Martin-Buitrago, L., Nordlander, A., Arellano, E., Zambrotta, G. P. M., Ammatuna, E., Cabirta, A., Sacchi, M. V., Rodrigues, R. N., Hersby, D. S., Hanakova, M., Rahimli, L., Cordoba, R., Cornely, O. A., Pagano, Livio, Marques De, Almeida, Hernandez-Rivas, Marques De Almeida, J., Hernandez-Rivas, J. A., Guidetti, A., Finizio, O., Stojanoski, Z., Cvetanoski, M., Meletiadis, J., De Jonge, N., Antic, D., Ali, N., Tisi, M. C., Serrano, L., Plantefeve, G., Khanna, N., Hoenigl, M., Cernan, M., Miranda-Castillo, C., Fernandez-Galan, M., Serris, A., Erben, N., Dulery, R., Aujayeb, A., Papa, M. V., Novak, J., Delia, M., Sapienza, G., Reizine, F., Omrani, A. S., Di Blasi, R., Lamure, S., Drgona, L., Coppola, N., Batinic, J., Al-Khabori, M., Ribera-Santa Susana, J. -M., Piedimonte, M., Loureiro-Amigo, J., Fouquet, G., Fazzi, R., Danion, F., Schubert, J., Hoell-Neugebauer, B., Bahr, N. C., Yahia, A. O., Torres-Atienza, A., Rinaldi, I., Popova, M., Ommen, H. -B., Mitra, M. E., Mikulska, M., Lacej, I., Khostelidi, S., Win, S., Vinh, D., Saleh, M., Prattes, J., Jindra, P., Guolo, F., Della Pepa, R., Chelysheva, E., Zdziarski, P., Wai-Man, V., Soto-Silva, A., Orth, H. M., Malak, S., Lorenzo De La Pena, L., Kolditz, M., Kho, C. S., Heath, C. H., Groh, A., Gavriilaki, E., Fung, M., Egger, M., De Kort, E., De Cabo, E., Cushion, T., Chowdhury, F. R., Ceesay, M. M., Brehon, M., Varricchio, G., Tafuri, A., Jimenez-Lorenzo, M. -J., Klimko, N., Tsirigotis, P., Antoniadou, A., Vehreschild, M., Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Objectives: Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail. Methods: We analyzed elderly patients (age groups: 65-70, 71-75, 76-80, and >80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022. Univariable and multivariable Cox regression models were conducted to identify factors influencing death in COVID-19 patients with hematological malignancy. Results: The study included data from 3,603 elderly patients (aged 65 or older) with hematological malignancy, with a majority being male (58.1%) and a significant proportion having comorbidities. The patients were divided into four age groups, and the analysis assessed COVID-19 outcomes, vaccination status, and other variables in relation to age and pandemic waves. The 90-day survival rate for patients with COVID-19 was 71.2%, with significant differences between groups. The pandemic waves had varying impacts, with the first wave affecting patients over 80 years old, the second being more severe in 65-70, and the third being the least severe in all age groups. Factors contributing to 90-day mortality included age, comorbidities, lymphopenia, active malignancy, acute leukemia, less than three vaccine doses, severe COVID-19, and using only corticosteroids as treatment. Conclusion: These data underscore the heterogeneity of elderly hematological patients, highlight the different impacts of COVID-19 waves and the pivotal importance of vaccination, and may help in planning future healthcare efforts.
- Published
- 2023
32. Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
- Author
-
Menna, P., Marchesi, F., Cattaneo, C., Candoni, A., Delia, M., Nadali, G., Vatteroni, A., Pasciolla, C., Perrone, S., Verga, L., Armiento, D., Delprincipe, M. I., Fracchiolla, N. S., Salvatorelli, E., Lupisella, S., Terrenato, I., Busca, A., Minotti, G., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), Menna, P., Marchesi, F., Cattaneo, C., Candoni, A., Delia, M., Nadali, G., Vatteroni, A., Pasciolla, C., Perrone, S., Verga, L., Armiento, D., Delprincipe, M. I., Fracchiolla, N. S., Salvatorelli, E., Lupisella, S., Terrenato, I., Busca, A., Minotti, G., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Midostaurin is used in combination with chemotherapy to treat patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Chemotherapy-induced neutropenia exposes these patients to a significant risk of invasive fungal infections (IFIs). International guidelines recommend primary antifungal prophylaxis with posaconazole (PCZ) but nested analysis of a phase III trial showed that strong PCZ inhibition of CYP3A4 diminished midostaurin metabolism and increased midostaurin plasma levels; however, midostaurin-related adverse events (AEs) were only moderately exacerbated. We conducted a prospective multicenter real-life study to evaluate (i) how often concerns around PCZ-midostaurin interactions made the hematologist prescribe antifungals other than PCZ, (ii) how remarkably PCZ increased midostaurin plasma levels, and (iii) how significantly PCZ-midostaurin interactions influenced hematologic and safety outcomes of induction therapy. Although the hematologists were blinded to pharmacokinetic findings, as many as 16 of 35 evaluable patients were prescribed antifungal prophylaxis with micafungin, weak CYP3A4 inhibitor, in place of PCZ (p < 0.001 for deviation from guidelines). In the 19 patients managed as per guidelines, PCZ-midostaurin interactions were more remarkable than previously characterized, such that at the end of induction therapy midostaurin minimum plasma concentration (Cmin) was greater than three times higher than reported; moreover, midostaurin Cmin, maximum plasma concentration, and area under the curve were more than or equal to four times higher with PCZ than micafungin. Hematologic outcomes (complete remission and duration of severe neutropenia) and safety outcomes (midostaurin-related any grade or grade ≥3 AEs) were nonetheless similar for patients exposed to PCZ or micafungin, as was the number of breakthrough IFIs. In waiting for randomized phase III trials of new prophylaxis regimens, these findings show that PCZ should remain the antifunga
- Published
- 2023
33. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
- Author
-
Pagano, Livio, Salmanton-Garcia, J., Marchesi, F., Blennow, O., Gomes da Silva, M., Glenthoj, A., van Doesum, J., Bilgin, Y. M., Lopez-Garcia, A., Itri, F., Nunes Rodrigues, R., Weinbergerova, B., Farina, F., Dragonetti, Giulia, Berg Venemyr, C., van Praet, J., Jaksic, O., Valkovic, T., Falces-Romero, I., Martin-Perez, S., Jimenez, M., Davila-Valls, J., Schonlein, M., Ammatuna, E., Meers, S., Delia, M., Stojanoski, Z., Nordlander, A., Lahmer, T., Imre Pinczes, L., Buquicchio, C., Piukovics, K., Ormazabal-Velez, I., Fracchiolla, N., Samarkos, M., Mendez, G. -A., Hernandez-Rivas, J. -A., Espigado, I., Cernan, M., Petzer, V., Lamure, S., di Blasi, R., Marques de Almedia, J., Dargenio, M., Biernat, M. M., Sciume, M., de Ramon, C., de Jonge, N., Batinic, J., Aujayeb, A., Marchetti, M., Fouquet, G., Fernandez, N., Zambrotta, G., Sacchi, M. V., Guidetti, A., Demirkan, F., Prezioso, L., Racil, Z., Nucci, M., Mladenovic, M., Lievin, R., Hanakova, M., Grafe, S., Sili, U., Machado, M., Cattaneo, C., Adzic-Vukicevic, T., Verga, L., Labrador, J., Rahimli, L., Bonanni, Matteo, Passamonti, F., Pagliuca, A., Corradini, P., Hoenigl, M., Koehler, P., Busca, A., Cornely, O. A., Serrano, L., Ribera-Santa Susana, J. -M., Meletiadis, J., Tsirigotis, P., Coppola, N., Mikulska, M., Erben, N., Besson, C., Merelli, M., Gonzalez-Lopez, T. -J., Loureiro-Amigo, J., Garcia-Vidal, C., Kort, E. D., Cuccaro, A., Zompi, S., Reizine, F., Finizio, O., Dulery, R., Calbacho, M., Abu-Zeinah, G., Malak, S., Zdziarski, P., Varrichio, G., Tragiannidis, A., Plantefeve, G., Duarte, R., Danion, F., Tisi, M. C., Sakellari, I., Karthaus, M., Groh, A., Fung, M., Emarah, Z., Coronel-Ayala, O. -F., Ann Chai, L. Y., Brehon, M., Bonuomo, V., Wolf, D., Wittig, J., Vehreschild, M., Papa, M. V., Neuhann, J., Jimenez-Lorenzo, M. -J., Grothe, J., Gavriilaki, E., Garcia-Sanz, R., Garcia-Pouton, N., El-Ashwah, S. S., Eggerer, M., Cordoba, R., Colak, G. M., Arellano, E., Hematology, Pagano L., Salmanton-García J., Marchesi F., Blennow O., Gomes da Silva M., Glenthøj A., van Doesum J., Bilgin Y. M. , López-García A., Itri F., et al., and Gilead Sciences
- Subjects
Internal Diseases ,Clinical Trials and Observations ,CELL BIOLOGY ,Cardiorespiratory Medicine and Haematology ,Sağlık Bilimleri ,Fundamental Medical Sciences ,Biochemistry ,İç Hastalıkları ,Clinical Medicine (MED) ,COVID-19 Testing ,BİYOKİMYA VE MOLEKÜLER BİYOLOJİ ,Biyokimya ,Monoclonal ,Klinik Tıp (MED) ,03.02. Klinikai orvostan ,Viral ,Lung ,Cancer ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,Lymphoid Neoplasia ,Myeloid Neoplasia ,Klinik Tıp ,Hücre Biyolojisi ,Temel Bilimler ,HEMATOLOJİ ,Life Sciences ,HÜCRE BİYOLOJİSİ ,Tıp ,MOLECULAR BIOLOGY & GENETICS ,Infectious Diseases ,Hematologic Neoplasms ,Medicine ,Natural Sciences ,Infection ,BIOCHEMISTRY & MOLECULAR BIOLOGY ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija ,Sitogenetik ,Biotechnology ,Adult ,Clinical Sciences ,Immunology ,Temel Tıp Bilimleri ,Histoloji-Embriyoloji ,Life Sciences (LIFE) ,Molecular Biology and Genetics ,Antiviral Agents ,Antibodies ,Vaccine Related ,Paediatrics and Reproductive Medicine ,HEMATOLOGY ,Biodefense ,Yaşam Bilimleri ,Health Sciences ,Humans ,CVOID19 ,Cytogenetic ,Free Research Articles ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,Moleküler Biyoloji ve Genetik ,Internal Medicine Sciences ,İmmünoloji ,SARS-CoV-2 ,Histology and Embryology ,Prevention ,COVID-19 ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology ,Settore MED/15 - MALATTIE DEL SANGUE ,Emerging Infectious Diseases ,Good Health and Well Being ,Yaşam Bilimleri (LIFE) ,Hematoloji ,Immunization - Abstract
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals., EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
- Published
- 2022
- Full Text
- View/download PDF
34. Refinement of MRD Assessment in Hairy Cell Leukemia by Integrated Molecular and Flow Cytometry Analysis
- Author
-
Urbani, G., Allegretti, M., De Pascale, V., Masi, S., Pasquale, A., Marchesi, F., Mengarelli, A., Pisani, F., Blandino, G., Renzi, D., and Cordone, I.
- Published
- 2023
- Full Text
- View/download PDF
35. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
- Author
-
Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Ráčil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux MP, Verga L, Weinbergerová B, Szotkovski T, Da Silva MG, Fracchiolla N, De Jonge N, Collins G, Marchetti M, Magliano G, García-Vidal C, Biernat MM, Van Doesum J, Machado M, Demirkan F, Al- Khabori M, Žák P, Víšek B, Stoma I, Méndez GA, Maertens J, Khanna N, Espigado I, Dragonetti G, Fianchi L, Del Principe MI, Cabirta A, Ormazabal- Vélez I, Jaksic O, Buquicchio C, Bonuomo V, Batinić J, Omrani AS, Lamure S, Finizio O, Fernández N, Falces-Romero I, Blennow O, Bergantim R, Ali N, Win S, Van Praet J, Tisi MC, Shirinova A, Schönlein M, Prattes J, Piedimonte M, Petzer V, Navrátil M, Kulasekararaj A, Jindra P, Sramek J, Glenthøj A, Fazzi R, De Ramón-Sánchez C, Cattaneo C, Calbacho M, Bahr NC, El-Ashwah S, Cordoba R, Hanakova M, Zambrotta G, Sciumè M, Booth S, Rodrigues RN, Sacchi MV, García-Poutón N, Martín- González JA, Khostelidi S, Gräfe S, Rahimli L, Ammatuna E, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely OA, Pagano L and EPICOVIDEHA working group.
- Subjects
AML Covid 19 - Abstract
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died ; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80% ; P
- Published
- 2023
- Full Text
- View/download PDF
36. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome
- Author
-
Zacchetti L., Longhi L., Bianchi I., Di Matteo M., Russo F., Gandini L., Manesso L., Monti M., Cosentini R., Di Marco F., Fagiuoli S., Grazioli L., Gritti P., Previdi F., Senni M., Ranieri M., Lorini L., Rota A., Martinelli A., Pugni P., Marino A., Colombo G., Damiani M., Ferrari D., Bonacina D., Corbella D., Poli G., Cantu D., Ferri F., Brivio M., Bonanomi E., Fabretti F., Benigni A., Brambillasca P., Scarpa L., Marchesi F., Zacchetti, L, Longhi, L, Bianchi, I, Di Matteo, M, Russo, F, Gandini, L, Manesso, L, Monti, M, Cosentini, R, Di Marco, F, Fagiuoli, S, Grazioli, L, Gritti, P, Previdi, F, Senni, M, Ranieri, M, Lorini, L, Rota, A, Martinelli, A, Pugni, P, Marino, A, Colombo, G, Damiani, M, Ferrari, D, Bonacina, D, Corbella, D, Poli, G, Cantu, D, Ferri, F, Brivio, M, Bonanomi, E, Fabretti, F, Benigni, A, Brambillasca, P, Scarpa, L, and Marchesi, F
- Subjects
Pulmonary and Respiratory Medicine ,Respiratory Distress Syndrome ,Acute respiratory distress syndrome ,Coronaviru ,COVID-19 ,Prone positioning ,Respiration, Artificial ,Coronavirus ,Positive-Pressure Respiration ,Phenotype ,Sars coronaviru ,Settore ING-INF/04 - Automatica ,Acute lung injury ,Lung compliance ,Sars coronavirus ,Humans ,Lung Compliance - Abstract
Background Coronavirus disease 2019-associated acute respiratory distress syndrome (COVID-19 ARDS) seems to differ from the “classic ARDS”, showing initial significant hypoxemia in the face of relatively preserved compliance and evolving later in a scenario of poorly compliant lungs. We tested the hypothesis that in patients with COVID-19 ARDS, the initial value of static compliance of respiratory system (Crs) (1) depends on the previous duration of the disease (i.e., the fewer days of illness, the higher the Crs and vice versa) and (2) identifies different lung patterns of time evolution and response to prone positioning. Methods This was a single-center prospective observational study. We enrolled consecutive mechanically ventilated patients with a diagnosis of COVID-19 who met ARDS criteria, admitted to intensive care unit (ICU). Patients were divided in four groups based on quartiles of initial Crs. Relationship between Crs and the previous duration of the disease was evaluated. Respiratory parameters collected once a day and during prone positioning were compared between groups. Results We evaluated 110 mechanically ventilated patients with a diagnosis of COVID-19 who met ARDS criteria admitted to our ICUs. Patients were divided in groups based on quartiles of initial Crs. The median initial Crs was 41 (32–47) ml/cmH2O. No association was found between the previous duration of the disease and the initial Crs. The Crs did not change significantly over time within each quartile. Positive end-expiratory pressure (PEEP) and driving pressure were respectively lower and greater in patients with lower Crs. Prone positioning significantly improved PaO2/FiO2 in the 4 groups, however it increased the Crs significantly only in patients in lower quartile of Crs. Conclusions In our cohort, the initial Crs is not dependent on the previous duration of COVID-19 disease. Prone positioning improves oxygenation irrespective to initial Crs, but it ameliorates respiratory mechanics only in patients with lower Crs.
- Published
- 2022
- Full Text
- View/download PDF
37. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV
- Author
-
Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti, Coviello E, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi, Patrizia, Cattaneo, Chiara, Ferretti, Virginia Valeria, Mina, Roberto, Ferreri, Andrés José María, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, Scattolin, Anna Maria, Vannucchi, Alessandro Maria, Gambacorti-Passerini, Carlo, Musto, Pellegrino, Gherlinzoni, Filippo, Cuneo, Antonio, Pinto, Antonello, Trentin, Livio, Bocchia, Monica, Galimberti, Sara, Coviello, Elisa, Tisi, Maria Chiara, Morotti, Alessandro, Falini, Brunangelo, Turrini, Mauro, Tafuri, Agostino, Billio, Atto, Gentile, Massimo, Lemoli, Roberto Massimo, Venditti, Adriano, Della Porta, Matteo Giovanni, Lanza, Francesco, Rigacci, Luigi, Tosi, Patrizia, Mohamed, Sara, Corso, Alessandro, Luppi, Mario, Giuliani, Nicola, Busca, Alessandro, Pagano, Livio, Bruno, Raffaele, Grossi, Paolo Antonio, Corradini, Paolo, Passamonti, Francesco, and Arcaini, Luca
- Subjects
Cancer Research ,Lymphoma ,Coinfection ,COVID-19 ,Hematology ,General Medicine ,Settore MED/15 ,hematological malignancie ,secondary infections ,Settore MED/15 - MALATTIE DEL SANGUE ,COVID-19 Testing ,Oncology ,Hematologic Neoplasms ,secondary infection ,outcome ,Humans ,hematological malignancies ,Aged - Abstract
The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.
- Published
- 2022
38. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
- Author
-
Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., Vannucchi A. M., Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., and Vannucchi A. M.
- Abstract
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
- Published
- 2021
39. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study
- Author
-
Marchesi, F, Tendas, A, Giannarelli, D, Viggiani, C, Gumenyuk, S, Renzi, D, Franceschini, L, Caffarella, G, Rizzo, M, Palombi, F, Pisani, F, Romano, A, Spadea, A, Papa, E, Canfora, M, Pignatelli, A, Cantonetti, M, Arcese, W, and Mengarelli, A
- Published
- 2017
- Full Text
- View/download PDF
40. Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry
- Author
-
Della Pepa, Roberta, Picardi, M., Sorà, F., Stamouli, M., Busca, A., Candoni, A., Delia, M., Fanci, R., Perriello, V., Zancanella, M., Nosari, A., Salutari, P., Marchesi, F., Pane, F., Pagano, L., and on behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)
- Published
- 2016
- Full Text
- View/download PDF
41. Occurrence of SARS-CoV-2 infection among healthcare personnel: results from an early systematic review and meta-analysis
- Author
-
Riccò, M., Gualerzi, G., Ranzieri, S., Peruzzi, S., Valente, M., Marchesi, F., Bragazzi, N. L., Signorelli, C., Riccò, M., Gualerzi, G., Ranzieri, S., Peruzzi, S., Valente, M., Marchesi, F., Bragazzi, N. L., and Signorelli, C.
- Subjects
Reviews/Focus on ,healthcare workers ,SARS-CoV-2 ,Health Personnel ,coronavirus ,COVID-19 ,Humans ,epidemiology ,Serologic Tests ,Delivery of Health Care - Abstract
Background. SARS-CoV-2 infection has become a global public health concern globally. Even though Healthcare Workers (HCWs) are supposedly at increased risk for SARS-CoV-2 infection, to date no pooled evidence has been collected. Materials and Methods. We searched online electronic databases (PubMed, Embase, medRxiv.org for pre-prints) for all available contribution (up to May 20, 2019). Two Authors independently screened articles and extracted the data. The pooled prevalence of SARS-CoV-2 was analyzed using the random-effects model. The possible sources of heterogeneity were analyzed through subgroup analysis, and meta-regression. Results. The overall pooled prevalence of SARS-CoV-2 was 3.5% (95%CI 1.8–6.6) for studies based on molecular assays, 5.5% (95%CI 2.1–14.1) for studies based on serological assays, and 6.5% (95%CI 2.5–15.6) for point-of-care capillary blood tests. Among subgroups, serological tests identified higher risk for SARS-CoV-2 seropositivity in physicians than in nurses (OR 1.436, 95%CI 1.026 to 2.008). Regression analysis indicated the possible presence of publication bias only for molecular tests (t -3.3526, p-value 0.002648). Conclusions. The overall pooled prevalence of SARS-CoV-2 was lower than previously expected, but available studies were affected by significant heterogeneity, and the molecular studies by significant publication bias. Therefore, further high-quality research in the field is warranted. (www.actabiomedica.it)
- Published
- 2021
42. SARS-CoV-2 Infection among Patients with Mastocytosis: An EPICOVIDEHA Report
- Author
-
Criscuolo, M, primary, Salmanton-García, J, additional, Fracchiolla, N, additional, Dragonetti, G, additional, Khanna, N, additional, Weinbergerová, B, additional, Schönlein, M, additional, Machado, M, additional, Labrador, J, additional, Kolditz, M, additional, Itri, F, additional, Gomes da Silva, M, additional, Bonuomo, V, additional, Sciumè, M, additional, Nunes Rodrigues, R, additional, Gräfe, S, additional, Marchesi, F, additional, Cornely, OA, additional, and Pagano, L, additional
- Published
- 2022
- Full Text
- View/download PDF
43. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- Author
-
Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., Corradini P., Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., and Corradini P.
- Abstract
Background: Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods: This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and the prospective part of the study is ongoing. Findings: We enrolled 536 patients with a median follow-up of 20 days (IQR 10–34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77–2·34) in our whole study cohort and 3·72 (2·86–4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1–44·9). Older age (hazard ratio 1·03, 95% CI 1·01–1·05); progressive disease status (2·10, 1·41–3·12); diagnosis of
- Published
- 2020
44. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
- Author
-
Blennow, O., Salmanton-García, J., Nowak, P., Itri, F., Doesum, J. Van, López-García, A., Farina, F., Jaksic, O., Pinczés, L.I., Bilgin, Y.M., Falces-Romero, I., Jiménez, M., Ormazabal-Vélez, I., Weinbergerová, B., Duléry, R., Stojanoski, Z., Lahmer, T., Fernández, N., Hernández-Rivas, J., Petzer, V., Jonge, N. de, Glenthøj, A., Ramón, C. De, Biernat, M.M., Fracchiolla, N., Aujayeb, A., Praet, J. Van, Schönlein, M., Méndez, G.A., Cattaneo, C., Guidetti, A., Sciumè, M., Ammatuna, E., Cordoba, R., García-Poutón, N., Gräfe, S., Cabirta, A., Wolf, D., Nordlander, A., García-Sanz, R., Delia, M., Venemyr, C. Berg, Brones, C., Blasi, R. Di, Kort, E.A. de, Meers, S., Lamure, S., Serrano, L., Merelli, M., Coppola, N., Bergantim, R., Besson, C., Kohn, M., Petiti, J., Garcia-Vidal, C., Dargenio, M., Danion, F., Machado, M., Bailén-Almorox, R., Hoenigl, M., Dragonetti, G., Chai, L.Y., Kho, C.S., Bonanni, M., Liévin, R., Marchesi, F., Cornely, O.A., Pagano, L., Blennow, O., Salmanton-García, J., Nowak, P., Itri, F., Doesum, J. Van, López-García, A., Farina, F., Jaksic, O., Pinczés, L.I., Bilgin, Y.M., Falces-Romero, I., Jiménez, M., Ormazabal-Vélez, I., Weinbergerová, B., Duléry, R., Stojanoski, Z., Lahmer, T., Fernández, N., Hernández-Rivas, J., Petzer, V., Jonge, N. de, Glenthøj, A., Ramón, C. De, Biernat, M.M., Fracchiolla, N., Aujayeb, A., Praet, J. Van, Schönlein, M., Méndez, G.A., Cattaneo, C., Guidetti, A., Sciumè, M., Ammatuna, E., Cordoba, R., García-Poutón, N., Gräfe, S., Cabirta, A., Wolf, D., Nordlander, A., García-Sanz, R., Delia, M., Venemyr, C. Berg, Brones, C., Blasi, R. Di, Kort, E.A. de, Meers, S., Lamure, S., Serrano, L., Merelli, M., Coppola, N., Bergantim, R., Besson, C., Kohn, M., Petiti, J., Garcia-Vidal, C., Dargenio, M., Danion, F., Machado, M., Bailén-Almorox, R., Hoenigl, M., Dragonetti, G., Chai, L.Y., Kho, C.S., Bonanni, M., Liévin, R., Marchesi, F., Cornely, O.A., and Pagano, L.
- Abstract
Contains fulltext : 282572.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
45. Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population-on behalf of the Italian Research Group for Gastric Cancer
- Author
-
Lombardi, P. M., Bernasconi, D., Baiocchi, G. L., Berselli, M., Biondi, Alberto, Castoro, C., Catarci, Marco, Degiuli, M., Fumagalli Romario, U., Giacopuzzi, S., Marchesi, F., Marrelli, D., Mazzola, M., Molfino, S., Olmi, S., Rausei, S., Rosa, Fausto, Rosati, R., Roviello, F., Santi, Samuele, Solaini, L., Staderini, F., Vigano, J., Ferrari, G., Agnes, Annamaria, Alfieri, Sergio, Alloggio, M., Bencivenga, M., Benedetti, M., Bottari, A., Cianchi, F., Cocozza, E., Dalmonte, G., De Martini, P., De Pascale, S., Desio, M., Emiliani, G., Ercolani, G., Galli, F., Garosio, I., Giani, A., Gualtierotti, M., Marano, L., Morgagni, P., Peri, A., Puccetti, F., Reddavid, R., Uccelli, M., Biondi A. (ORCID:0000-0002-2470-7858), Catarci M., Rosa F. (ORCID:0000-0002-7280-8354), Santi S., Agnes A., Alfieri S. (ORCID:0000-0002-0404-724X), Lombardi, P. M., Bernasconi, D., Baiocchi, G. L., Berselli, M., Biondi, Alberto, Castoro, C., Catarci, Marco, Degiuli, M., Fumagalli Romario, U., Giacopuzzi, S., Marchesi, F., Marrelli, D., Mazzola, M., Molfino, S., Olmi, S., Rausei, S., Rosa, Fausto, Rosati, R., Roviello, F., Santi, Samuele, Solaini, L., Staderini, F., Vigano, J., Ferrari, G., Agnes, Annamaria, Alfieri, Sergio, Alloggio, M., Bencivenga, M., Benedetti, M., Bottari, A., Cianchi, F., Cocozza, E., Dalmonte, G., De Martini, P., De Pascale, S., Desio, M., Emiliani, G., Ercolani, G., Galli, F., Garosio, I., Giani, A., Gualtierotti, M., Marano, L., Morgagni, P., Peri, A., Puccetti, F., Reddavid, R., Uccelli, M., Biondi A. (ORCID:0000-0002-2470-7858), Catarci M., Rosa F. (ORCID:0000-0002-7280-8354), Santi S., Agnes A., and Alfieri S. (ORCID:0000-0002-0404-724X)
- Abstract
Background Oncologic outcomes after laparoscopic gastrectomy for advanced gastric cancer in the West have been poorly investigated. The aim of the present study was to compare survival outcomes in patients undergoing curative-intent laparoscopic and open gastrectomy for advanced gastric cancer in several centres belonging to the Italian Research Group for Gastric Cancer. Methods Data of patients operated between 2015 and 2018 were retrospectively analysed. Propensity Score Matching was performed to balance baseline characteristics of patients undergoing laparoscopic and open gastrectomy. The primary endpoint was 3-year overall survival. Secondary endpoints were 3-year disease-free survival and short-term outcomes. Multivariable regression analyses for survival were conducted. Results Data were retrieved from 20 centres. Of the 717 patients included, 438 patients were correctly matched, 219 per group. The 3-year overall survival was 73.6% and 68.7% in the laparoscopic and open group, respectively (p = 0.40). When compared with open gastrectomy, laparoscopic gastrectomy showed comparable 3-year disease-free survival (62.8%, vs 58.9%, p = 0.40), higher rate of return to intended oncologic treatment (56.9% vs 40.2%, p = 0.001), similar 30-day morbidity/mortality. Prognostic factors for survival were ASA Score >= 3, age-adjusted Charlson Comorbidity Index >= 5, lymph node ratio >= 0.15, p/ypTNM Stage III and return to intended oncologic treatment. Conclusions Laparoscopic gastrectomy for advanced gastric cancer offers similar rates of survival when compared to open gastrectomy, with higher rates of return to intended oncologic treatment. ASA score, age-adjusted Charlson Comorbidity Index, lymph node ratio, return to intended oncologic treatment and p/ypTNM Stage, but not surgical approach, are prognostic factors for survival.
- Published
- 2022
46. A High-Risk Profile for Invasive Fungal Infections Is Associated with Altered Nasal Microbiota and Niche Determinants
- Author
-
Costantini, C., Nunzi, E., Spolzino, A., Merli, F., Facchini, L., Spadea, A., Melillo, L., Codeluppi, K., Marchesi, F., Marchesini, G., Valente, D., Dragonetti, Giulia, Nadali, G., Englmaier, L., Coufalikova, K., Spacil, Z., Bellet, M. M., Pariano, M., Renga, G., Stincardini, C., D'Onofrio, F., Bozza, S., Pagano, Livio, Aversa, F., Romani, L., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Costantini, C., Nunzi, E., Spolzino, A., Merli, F., Facchini, L., Spadea, A., Melillo, L., Codeluppi, K., Marchesi, F., Marchesini, G., Valente, D., Dragonetti, Giulia, Nadali, G., Englmaier, L., Coufalikova, K., Spacil, Z., Bellet, M. M., Pariano, M., Renga, G., Stincardini, C., D'Onofrio, F., Bozza, S., Pagano, Livio, Aversa, F., Romani, L., Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
It is becoming increasingly clear that the communities of microorganisms that populate the surfaces exposed to the external environment, termed microbiota, are key players in the regulation of pathogen-host cross talk affecting the onset as well as the outcome of infectious diseases. We have performed a multicenter, prospective, observational study in which nasal and oropharyngeal swabs were collected for microbiota predicting the risk of invasive fungal infections (IFIs) in patients with hematological malignancies. Here, we demonstrate that the nasal and oropharyngeal microbiota are different, although similar characteristics differentiate high-risk from low-risk samples at both sites. Indeed, similar to previously published results on the oropharyngeal microbiota, high-risk samples in the nose were characterized by low diversity, a loss of beneficial bacteria, and an expansion of potentially pathogenic taxa, in the presence of reduced levels of tryptophan (Trp). At variance with oropharyngeal samples, however, low Trp levels were associated with defective host-derived kynurenine production, suggesting reduced tolerance mechanisms at the nasal mucosal surface. This was accompanied by reduced levels of the chemokine interleukin-8 (IL-8), likely associated with a reduced recruitment of neutrophils and impaired fungal clearance. Thus, the nasal and pharyngeal microbiomes of hematological patients provide complementary information that could improve predictive tools for the risk of IFI in hematological patients.
- Published
- 2022
47. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV
- Author
-
Zappasodi, P., Cattaneo, C., Valeria Ferretti, V., Mina, R., Jose Maria Ferreri, A., Merli, F., Oberti, M., Krampera, M., Romano, A., Zerbi, C., Ferrari, J., Cavo, M., Salvini, M., Bertu, L., Stefano Fracchiolla, N., Marchesi, F., Massaia, M., Marasco, V., Cairoli, R., Maria Scattolin, A., Maria Vannucchi, A., Gambacorti-Passerini, C., Musto, P., Gherlinzoni, F., Cuneo, A., Pinto, A., Trentin, L., Bocchia, M., Galimberti, S., Coviello, E., Chiara Tisi, M., Morotti, A., Falini, B., Turrini, M., Tafuri, A., Billio, A., Gentile, M., Massimo Lemoli, R., Venditti, A., Giovanni Della Porta, M., Lanza, F., Rigacci, L., Tosi, P., Mohamed, S., Corso, A., Luppi, M., Giuliani, N., Busca, A., Pagano, Livio, Bruno, R., Antonio Grossi, P., Corradini, P., Passamonti, F., Arcaini, L., Pagano L. (ORCID:0000-0001-8287-928X), Zappasodi, P., Cattaneo, C., Valeria Ferretti, V., Mina, R., Jose Maria Ferreri, A., Merli, F., Oberti, M., Krampera, M., Romano, A., Zerbi, C., Ferrari, J., Cavo, M., Salvini, M., Bertu, L., Stefano Fracchiolla, N., Marchesi, F., Massaia, M., Marasco, V., Cairoli, R., Maria Scattolin, A., Maria Vannucchi, A., Gambacorti-Passerini, C., Musto, P., Gherlinzoni, F., Cuneo, A., Pinto, A., Trentin, L., Bocchia, M., Galimberti, S., Coviello, E., Chiara Tisi, M., Morotti, A., Falini, B., Turrini, M., Tafuri, A., Billio, A., Gentile, M., Massimo Lemoli, R., Venditti, A., Giovanni Della Porta, M., Lanza, F., Rigacci, L., Tosi, P., Mohamed, S., Corso, A., Luppi, M., Giuliani, N., Busca, A., Pagano, Livio, Bruno, R., Antonio Grossi, P., Corradini, P., Passamonti, F., Arcaini, L., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.
- Published
- 2022
48. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
- Author
-
Pagano, Livio, Criscuolo, Marianna, Broccoli, A., Piciocchi, A., Varettoni, M., Galli, Eugenio, Anastasia, A., Cantonetti, M., Trentin, L., Kovalchuk, S., Orsucci, L., Frustaci, A., Spolzino, A., Volpetti, S., Annibali, O., Storti, Sergio, Stelitano, C., Marchesi, F., Offidani, M., Casadei, B., Nizzoli, M. E., De Luca, M. L., Fianchi, Luana, Motta, M., Guarnera, L., Simonetti, E., Visentin, A., Vassallo, F., Deodato, M., Sarlo, C., Olivieri, A., Falini, B., Pulsoni, A., Tiacci, E., Zinzani, P. L., Pagano L. (ORCID:0000-0001-8287-928X), Criscuolo M., Galli E., Storti S. (ORCID:0000-0002-4374-3985), Fianchi L., Pagano, Livio, Criscuolo, Marianna, Broccoli, A., Piciocchi, A., Varettoni, M., Galli, Eugenio, Anastasia, A., Cantonetti, M., Trentin, L., Kovalchuk, S., Orsucci, L., Frustaci, A., Spolzino, A., Volpetti, S., Annibali, O., Storti, Sergio, Stelitano, C., Marchesi, F., Offidani, M., Casadei, B., Nizzoli, M. E., De Luca, M. L., Fianchi, Luana, Motta, M., Guarnera, L., Simonetti, E., Visentin, A., Vassallo, F., Deodato, M., Sarlo, C., Olivieri, A., Falini, B., Pulsoni, A., Tiacci, E., Zinzani, P. L., Pagano L. (ORCID:0000-0001-8287-928X), Criscuolo M., Galli E., Storti S. (ORCID:0000-0002-4374-3985), and Fianchi L.
- Abstract
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), although relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data of HCL patients treated with 2CDA between March 1991 and May 2019 at 18 Italian Hematological centers: 513 patients were evaluable for study purpose. The median age was 54 years (range 24–88) and ECOG was 0 in 84.9% of cases. A total of 330 (64.3%) patients received 2CDA intravenously and 183 (35.7%) subcutaneously. ORR was 91.8%: CR was obtained in 335 patients (65.3%), PR in 96 (18.7%), and hematological response in 40 (7.8%) patients; in 42 (8.2%) no response was observed. Hemoglobin value (p = 0.044), frequency of circulating hairy cells (p = 0.039), recovery of absolute neutrophil count (p = 0.006), and normalization of spleen (p ≤ 0.001) were associated with CR compared to PR in univariable analysis. At a median follow-up of 6.83 years (range 0.04–28.52), the median time to relapse was 12.2 years. A significant difference in duration of response was identified between patients that obtained a CR and PR (19.4 years versus 4.8 years, p < 0.0001). Non-hematological grade 3 or higher early toxicity was reported in 103 (20.1%) patients. Median OS was not reached: 95.3%, 92.4%, and 81.8% of patients were estimated to be alive at 5, 10, and 15 years, respectively. Forty-nine patients died (9.5%), following an infection in 14 cases (2.7%), natural causes in 14 (2.7%), cardiovascular events in 13 (2.5%), a second neoplasm in 6 (1.2%), and progression of HCL in 2 cases (0.4%). Following treatment of HCL with 2CDA, 80% of patients are estimated to be alive 15 years after diagnosis.
- Published
- 2022
49. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
- Author
-
Cattaneo, C., Marchesi, F., Terrenato, I., Bonuomo, V., Fracchiolla, N. S., Delia, M., Criscuolo, Marianna, Candoni, A., Prezioso, L., Facchinelli, D., Pasciolla, C., Del Principe, M. I., Dargenio, M., Buquicchio, C., Mitra, M. E., Farina, F., Borlenghi, E., Nadali, G., Gagliardi, V. P., Fianchi, Luana, Sciume, M., Menna, P., Busca, A., Rossi, G., Pagano, Livio, Criscuolo M., Fianchi L., Pagano L. (ORCID:0000-0001-8287-928X), Cattaneo, C., Marchesi, F., Terrenato, I., Bonuomo, V., Fracchiolla, N. S., Delia, M., Criscuolo, Marianna, Candoni, A., Prezioso, L., Facchinelli, D., Pasciolla, C., Del Principe, M. I., Dargenio, M., Buquicchio, C., Mitra, M. E., Farina, F., Borlenghi, E., Nadali, G., Gagliardi, V. P., Fianchi, Luana, Sciume, M., Menna, P., Busca, A., Rossi, G., Pagano, Livio, Criscuolo M., Fianchi L., and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. During induction, the incidence of probable/proven and possible IFD was 10.5% and 9.7%, respectively; no statistically significant difference was observed according to the different AF strategy adopted. The median duration of neutropenia was similar in patients with or without IFD. Proven/probable and possible IFD incidence was 2.4% and 1.8%, respectively, during consolidation. Age was the only risk factor for IFD (OR, 95% CI, 1.10 [1.03–1.19]) and complete remission achievement after first induction the only one for survival (OR, 95% CI, 5.12 [1.93–13.60]). The rate of midostaurin discontinuation was similar across different AF strategies. The IFD attributable mortality during induction was 8.3%. In conclusion, the 20.2% overall incidence of IFD occurring in FLT3-mutated AML during induction with chemotherapy + midostaurin, regardless of AF strategy type, was noteworthy, and merits further study, particularly in elderly patients.
- Published
- 2022
50. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Infante, M. S., Salmanton-Garcia, J., Fernandez-Cruz, A., Marchesi, F., Jaksic, O., Weinbergerova, B., Besson, C., Duarte, R. F., Itri, F., Valkovic, T., Szotkovski, T., Busca, A., Guidetti, A., Glenthoj, A., Collins, G. P., Bonuomo, V., Sili, U., Seval, G. C., Machado, M., Cordoba, R., Blennow, O., Abu-Zeinah, G., Lamure, S., Kulasekararaj, A., Falces-Romero, I., Cattaneo, C., Van Doesum, J., Piukovics, K., Omrani, A. S., Magliano, G., Ledoux, M. -P., de Ramon, C., Cabirta, A., Verga, L., Lopez-Garcia, A., Da Silva, M. G., Stojanoski, Z., Meers, S., Lahmer, T., Martin-Perez, S., Davila-Vals, J., Van Praet, J., Samarkos, M., Bilgin, Y. M., Karlsson, L. K., Batinic, J., Nordlander, A., Schonlein, M., Hoenigl, M., Racil, Z., Mladenovic, M., Hanakova, M., Zambrotta, G. P. M., De Jonge, N., Adzic-Vukicevic, T., Nunes-Rodrigues, R., Prezioso, L., Navratil, M., Marchetti, M., Cuccaro, A., Calbacho, M., Giordano, A., Cornely, O. A., Hernandez-Rivas, J. -A., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), Infante, M. S., Salmanton-Garcia, J., Fernandez-Cruz, A., Marchesi, F., Jaksic, O., Weinbergerova, B., Besson, C., Duarte, R. F., Itri, F., Valkovic, T., Szotkovski, T., Busca, A., Guidetti, A., Glenthoj, A., Collins, G. P., Bonuomo, V., Sili, U., Seval, G. C., Machado, M., Cordoba, R., Blennow, O., Abu-Zeinah, G., Lamure, S., Kulasekararaj, A., Falces-Romero, I., Cattaneo, C., Van Doesum, J., Piukovics, K., Omrani, A. S., Magliano, G., Ledoux, M. -P., de Ramon, C., Cabirta, A., Verga, L., Lopez-Garcia, A., Da Silva, M. G., Stojanoski, Z., Meers, S., Lahmer, T., Martin-Perez, S., Davila-Vals, J., Van Praet, J., Samarkos, M., Bilgin, Y. M., Karlsson, L. K., Batinic, J., Nordlander, A., Schonlein, M., Hoenigl, M., Racil, Z., Mladenovic, M., Hanakova, M., Zambrotta, G. P. M., De Jonge, N., Adzic-Vukicevic, T., Nunes-Rodrigues, R., Prezioso, L., Navratil, M., Marchetti, M., Cuccaro, A., Calbacho, M., Giordano, A., Cornely, O. A., Hernandez-Rivas, J. -A., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
- Abstract
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.